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Background: Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants produced by incom-
plete combustion of organic materials. Pre-clinical and occupational studies have reported a positive association
of PAHswith oxidative stress, inflammation and subsequent development of atherosclerosis, a major underlying
risk factor for cardiovascular disease (CVD). The aim of the current study is to estimate the association between
levels of PAH biomarkers and CVD in a national representative sample of United States (US) adults.
Methods:We examined adult participants (≥20 years of age) from the merged US National Health and Nutrition
Examination Survey 2001–2010. Logistic regression models were used to estimate the associations of each uri-
nary PAHbiomarker and CVD. Post-exploratory structural equationmodelingwas then used to address the inter-
dependent response variables (angina, heart attack, stroke and coronary heart disease) as well as the
interdependencies of PAH biomarkers.
Results: PAH biomarkers were positively associated with cardiovascular disease in multiple logistic regression
models, although some associations were not statistically robust. Using structural equation modeling, latent
PAH exposure variable was positively associated with latent CVD level variable in the multivariable adjusted
model (β= 0.12; 95% CI: 0.03, 0.20).
Conclusion: A modest association between levels of PAH biomarkers and CVD was detected in US adults. Further
prospective studies with adequate sample size are needed to replicate or refute our findings.
© 2016 Elsevier Ltd. All rights reserved.
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1. Introduction
Despite advances in prevention, diagnosis and treatment,
cardiovascular disease (CVD) remains the number one cause of
mortality in United States (U.S.) adults (Kochanek et al., 2014). Car-
diovascular disease refers to numerous conditions, many of which
are related to atherosclerosis which develops when plaque builds
up in arterial walls, narrowing the arteries, and decreasing or
sometimes completely blocking tissue blood flow (Goff et al.,
2014). Such mechanisms can manifest themselves eventually with
adverse clinical outcomes such as coronary heart disease, angina
pectoris, heart attack, and stroke.
Epidemiological evidence suggests that exposure to particulatemat-
ter present in ambient air may pose an increased CVD risk in humans
(Bhatnagar, 2006). Polycyclic aromatic hydrocarbons (PAHs) are potent
atmospheric pollutants that occur in oil, coal, and tar deposits, and are
produced as byproducts of smoking, indoors and outdoors fuel burning
and food grilling (Liu et al., 2008; Ramesh et al., 2004; Simko, 2005).
Pre-clinical studies have reported a positive association between expo-
sure to PAHs, oxidative stress and atherosclerosis (Jeng et al., 2011;
Curfs et al., 2005). Epidemiological studies have found a positive associ-
ation between biomarkers of PAH exposure and serum inflammatory
markers of CVD (Alshaarawy et al., 2013). In addition, a positive associ-
ation between occupational exposure to PAHs and CVD morbidity and
mortality has been reported (Brucker et al., 2014; Burstyn et al.,
2005). However it is not clear if exposure to PAHs is associatedwith car-
diovascular disease in the general population.
With advantages of recent nationally representative sample surveys
and standardized data collection approaches with relatively large sam-
ples, we examined the association of PAH exposure and CVD in the
United States (US) general population. In addition, we used Structural
Equation Modeling approach trying to account for the interdepen-
dencies that must be confronted when different PAH biomarkers are
studied all at once. We also are accounting for the shared pathogenesis
of the response variables, namely the CVD events (angina, heart attack,
stroke and coronary heart disease).
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2. Methods
2.1. Study population
The National Health and Nutrition Examination Surveys (NHANES)
consist of a series of surveys designed by the National Center for Health
Statistics to continuously monitor the health status of the U.S. civilian
non-institutionalized population (United States Centers for Disease
Control and Prevention. National Center for Health Statistics (NCHS),
2010). The NHANES survey includes a stratified multistage probability
sample. Selection is based on counties, blocks, households and individ-
uals within households, and included oversampling of non-Hispanic
Blacks and Mexican Americans in order to provide stable estimates of
these groups. Data are collected for a two-year survey cycle.
In the current study we merged 2001–02, 2003–04, 2005–06,
2007–08 and 2009–10 data cycles, where eight analytes of PAHs
have been consistently measured. There were 27,584 participants
who were ≥20 years of age. Urinary PAH biomarkers were only mea-
sured in a subsample NHANES (n=7848). Participants with missing
information on serum cotinine and other covariates were not includ-
ed in the final model. This resulted in 7301 participants included in
the final analyses.
2.2. Outcome: Cardiovascular disease
A standardized medical condition questionnaire was administered
during the personal interview on a broad range of health conditions in-
cluding coronary heart disease, angina pectoris, heart attack and stroke.
Participants were asked “has a doctor or other health professional ever
told you that you have: coronary heart disease (CHD)/angina pectoris/
heart attack/stroke?” (These were 4 separate questions with the same
wording style). A participant was considered a CVD case if she/he an-
swered “yes” to any of the previous questions (0: no event occur-
rence/1: occurrence of at least one of the 4 clinical events).
2.3. Main exposure: Urinary levels of PAH biomarkers
Detailed urine specimen collection and processing instructions are
discussed in the NHANES Laboratory/Medical Technologists Procedures
Manual (United States Center for Disease Control and Prevention. Na-
tional Center for Health Statistics (NCHS), 2006). Specific analytes mea-
sured in NHANES are monohydroxy-PAH (OH-PAH). The procedure
involves enzymatic hydrolysis of urine, with extraction, derivatization
and analysis using capillary gas chromatography combined with high
resolution mass spectrometry (GCHRMS). This method uses isotope di-
lutionwith carbon-13 labeled internal standards. Ions fromeach analyte
and each carbon-13 labeled internal standard are monitored, and the
abundance of each ion is measured. The ratios of these ions are used
as criteria for evaluating the data. By evaluating these analytes in
urine, a measurement of the body burden from PAH exposure is obtain-
ed (A detailed description is available online at http://www.cdc.gov/
nchs/data/nhanes/nhanes_03_04/l31pah_c_met.pdf).
The limit of detection (LOD) was defined as the higher LOD calculat-
ed by two methods: (i) in direct relation to method blanks prepared in
parallel with the unknown samples, as 3 times the standard deviation of
the method blanks, and (ii) according to the instrumental detection
limit defined as the lowest point in the calibration curve (0.5 pg/uL, or
5 pg/mL in 2-mL urine samples) verified to give a signal with the S/N
equal to or N3. The limit of detection for each biomarker and each
data cycle can be found in the correspondingNHANES PAH lab files pro-
vided as supplementarymaterials. b1% of the study population has PAH
levels below lower detection limit.
Checks were made on the stability of the analytical system. Blanks
and standards, as well as quality control materials, were added to each
day's run sequence. The blank and standardwere analyzed at the begin-
ning of each run to check the system for possible contamination or in
the spiking solutions and/or reagents. Two QCLs and two QCHs were
prepared and analyzed at the beginning and the end of each run; their
concentrations were compared with acceptance criteria to assure the
proper operation of the analysis. Relative retention times were exam-
ined for the internal standard to ensure the choice of the correct chro-
matographic peak. More details on quality control procedures can be
found in the online supplemental materials.
Seven urinary low molecular weight PAH analytes (1-hydroxy-
napthol, 2-hydroxynapthol, 2-hydroxyfluorene, 3-hydroxyfluorene,
1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-hydroxyphenan-
threne) and one urinary high molecular weight analyte (1-hydroxy-
pyrene) were consistently available in NHANES 2001–10. Few other
biomarkers are not included in the current study because they were
not available in all years. All analytes were measured in the same unit;
ng/L. Urinary analytes of PAHs were corrected for creatinine concentra-
tion to reduce their variability by differences in urinary outputs. Urinary
levels of OH-PAH (ng/L) were divided by urinary creatinine level
(mg/dL) multiplied by 0.01, i.e., [(ng/L) ÷ (mg/dL ∗ 0.01)] and
expressed as nanogram per gram of creatinine (ng/g creatinine).
2.4. Covariates
In NHANES, information on age, gender, ethnic self-identification
(ESI), alcohol drinking, and poverty-income ratio (PIR) were obtained
during a standardized questionnaire during a home interview. Informa-
tion on anthropometric, physical and laboratory components were ob-
tained during the medical center examination. Body mass index (kg/
m2) was calculated as weight in kilograms divided by height in meters
squared. Serum total cholesterol (mg/dL) was measured enzymatically.
Serum cotinine (ng/mL) wasmeasured by an isotope dilution-high per-
formance liquid chromatography atmospheric pressure chemical ioni-
zation tandem mass spectrometry.
2.5. Statistical analysis
Exploratory data analysis techniqueswere used to assess the univar-
iate distribution of the study variables. Urinary PAH biomarker levels
were log-transformed as a result of their skewed distribution. We ran
logistic regressionmodels to calculate the odds ratio ([OR] and 95% con-
fidence interval [CI]) of self-reported CVD, for each urinary OH-PAH,
controlling for age (years) and sex. Final models were additionally ad-
justed for ESI (non-Hispanic White, non-Hispanic Black, Hispanics, and
all others), education (less than high school, high school, and above
high school), PIR, past-year alcohol drinking, BMI (normal, overweight,
obese), total cholesterol (mg/dL), and serum cotinine (ng/mL).
Structural Equation Modeling (SEM) was then used to construct a
series of models to estimate the association of PAHs and CVD level.
Buncher et al. discussed the application of SEM in Environmental Epide-
miology early in 1991 (Buncher et al., 1991). Structural equationmodel-
ing is a group of statistical methods that can model relationships
between one or more independent variables and one or more depen-
dent variables (Ullman, 2006). In the current analysis, PAH exposure is
a latent construct that is not directly measured but rather assessed indi-
rectly by PAH biomarkers. Instead of simply combining PAH biomarkers
by taking the sum and assigning equal weight to each biomarker, they
are employed as indicators of a latent construct and hence allows for es-
timation and removal of themeasurement error (Ullman, 2006). Limita-
tions of includingmultiple indicators of the same exposure in regression
models (such as collinearity) are accounted for in the SEM approach
(Gefen et al., 2000; Suhr, 2006). Similarly a latent construct for CVD
level was created via self-reported physician diagnosis of coronary
heart disease, angina, heart attack and/or stroke. For both constructs,
we defined factor loadings of 0.4 or greater as strongly correlated indi-
cators with the latent construct. This part of the model that relates the
measured variables to the corresponding latent construct is the mea-
surement part of the model. The hypothesized association between
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the two constructs is considered the structural part of the model,
regressing the latent CVD level construct as the response variable
on PAHs construct. In the initial models, we used maximum likeli-
hood estimation with robust standard errors (MLR). Because MLR
does not provide fit indices, in our post-exploratory step we used a
robust weighted least squares estimator (WLSMV). We determined
goodness of fit of the hypothesized models to the data by several fit
indices, including comparative fit index (CFI) ≥0.95 and root mean
square error approximation (RMSEA) ≤0.05. (Hu and Bentler, 1999;
Browne and Cudeck, 1992).
3. Results
Table 1 presents main characteristics of the study population. About
one half of the study populationwas female (51.2%). Themajority of the
study population was non-Hispanic White (71.1%). The arithmetic
mean of serum cotinine was 64.1 ng/mL. Table 2 presents selected per-
centiles of urinary OH-PAH biomarkers.
The main estimates of the study are presented in Table 3. Individ-
ual polycyclic aromatic hydrocarbons were positively associated
with self-reported CVD. However, only 1-hydroxynaphalene, 2-
hydroxynaphalene, 2-hydroxyfluorene and 3-hydroxyfluorene were
statistically robust.
Fig. 1 presents the baseline conceptual model regressing the latent
construct of CVD level as the response variables on the level of PAH ex-
posure, measured by eight urinary PAH biomarkers, controlling for age
(years) and sex. Results indicated a positive association between PAHs
and CVD (β= 0.12; 95% CI: 0.07, 0.17). The factor loadings were all
≥0.4 suggesting a strong correlation between the measures and each
corresponding construct.
Table 4 presents the association of PAH exposure level and CVD level
constructs additionally adjusting for ESI, education, PIR, alcohol drink-
ing, serum cotinine, total cholesterol and BMI. Our results did not
change appreciably (β=0.12; 95% CI: 0.03, 0.20), suggesting a positive
association between PAHs and CVD independent of the potential con-
founders studied here. Our results were consistent using either MLR or
WLSMV estimator. Table 4 also presents the association of PAH and
CVD constructs, stratified by sex, ESI and smoking status. Overall, PAH
was associated with CVD in the stratified subgroups, although some as-
sociationswere not statistically robust.We did not detect subgroup var-
iations in the estimates.
4. Discussion
Exposure to polycyclic aromatic hydrocarbons measured by eight
urinary PAHbiomarkers exhibited a positive associationwith cardiovas-
cular disease in adults ≥20 years of age independent of serum cotinine a
marker of nicotine exposure aswell as other potential confounders. Our
results are consistent with findings from previous occupational studies
which reported positive associations between exposure to PAHs, and is-
chemic heart diseases and cardiovascular mortality in occupations that
include likely exposure to PAHs (Brucker et al., 2014; Burstyn et al.,
2005; Thériault et al., 1988; Tüchsen et al., 1996). Xu et al. used
NHANES 2001–04 and reported a positive association between PAHbio-
markers and self-reported CVD using logistic regression modes (Xu
et al., 2010). In the current study, a latent CVD construct approach was
selected in addition to utilizing the standard binary approach (0: no
event occurrence/1: occurrence of at least one of the 4 clinical events)
to allow for consideration of the shared pathogenesis in the develop-
ment of CHD, angina, heart attack and stroke by means of a main com-
mon mechanism, namely atherosclerosis (Soler and Ruiz, 2010). A
latent PAH variable was also used to account for the interdependencies
of the PAH biomarkers as humans are usually exposed to mixtures of
PAHs (Elovaara et al., 1995). Due to the high cost of detecting parent
PAH levels in humans, the most commonly used biomarkers of PAH ex-
posure are urinary OH-PAH biomarkers. Urinary PAH biomarkers have
been previously found to correlate well with levels of exposure to
PAHs in the general population (Castano-Vinyals et al., 2004).
The mechanisms underlying the positive association of PAH expo-
sure and CVD remain unknown. Upon exposure to PAHs, detoxification
Table 1
Baseline characteristics of the study population (n = 7301). Data for the United States
adults ≥20 years of age based on the National Health and Nutrition Examination Survey
2001–2010.
Characteristics Mean values ± std error of mean or
sample size (weighted percentages)
Age (years) 46.2 ± 0.3
Sex (%)
Male 3550 (48.8)
Female 3751 (51.2)
Ethnic self-identification (%)
Non-Hispanic White 3693 (71.1)
Non-Hispanic Black 1378 (10.7)
Hispanics 1919 (12.8)
All others 311 (5.4)
Education (%)
Less than high school 2079 (18.3)
High school 1773 (25.1)
Above high school 3449 (56.6)
Income-poverty ratio b 1 1325 (12.6)
Past-year alcohol drinking (%) 4527 (67.6)
Body mass index (kg/m2)
b25 2184 (32.7)
25–29.9 2542 (33.4)
≥30 2575 (33.9)
Serum cotinine (ng/mL) 64.1 ± 2.8
Total cholesterol (mg/dL) 198.8 ± 0.8
Any CVD (%) 732 (7.9)
Coronary heart disease (%) 333 (3.7)
Angina (%) 218 (2.4)
Heart attack (%) 307 (3.3)
Stroke (%) 235 (2.4)
Table 2
Selected percentiles of urinary biomarkers of polycyclic aromatic hydrocarbons (ng/g cre-
atinine) among participants included in the final analysis. Data for theUnited States adults
≥20 years of age based on the National Health and Nutrition Examination Survey 2001–
2010.
Biomarkers 10th
percentile
Q1 Median Q3 90th
percentile
1-Hydroxynaphthalene 515 901 2081 6941 17,532
2-Hydroxynaphthalene 957 1576 3114 7454 15,717
2-Hydroxyfluorene 103 142 227 609 1630
3-Hydroxyfluorene 33 50 86 279 909
1-Hydroxyphenanthrene 62 90 141 231 361
2-Hydroxyphenanthrene 26 39 61 102 178
3-Hydroxyphenanthrene 36 53 85 158 297
1-Hydroxypyrene 26 44 83 159 313
Table 3
The association of PAH biomarkers and cardiovascular disease. Data for the United States
adults ≥20 years of age based on the National Health and Nutrition Examination Survey
2001–2010.
OH-PAH (ng/g
creatinine)
Age-sex adjusted odds
ratio (95% CI)
Multivariable-adjusted
odds ratio (95% CI)a
1-Hydroxynaphthalene 1.13 (1.07, 1.21) 1.11 (1.04, 1.18)
2-Hydroxynaphthalene 1.31 (1.19, 1.45) 1.22 (1.08, 1.38)
2-Hydroxyfluorene 1.31 (1.18, 1.45) 1.27 (1.12, 1.43)
3-Hydroxyfluorene 1.21 (1.11, 1.33) 1.18 (1.06, 1.32)
1-Hydroxyphenanthrene 1.12 (1.00, 1.25) 1.07 (0.94, 1.21)
2-Hydroxyphenanthrene 1.22 (1.09, 1.37) 1.11 (0.98, 1.26)
3-Hydroxyphenanthrene 1.13 (1.00, 1.27) 1.10 (0.96, 1.25)
1-Hydroxypyrene 1.20 (1.08, 1.33) 1.12 (1.00, 1.26)
a Adjusted for age (years), sex, ESI (non-Hispanic White, non-Hispanic Black, Hispanic
and all others), education (less than high school, high school and above high school), PIR,
past-year alcohol drinking, BMI (normal, overweight and obese), total cholesterol (mg/dL)
and serum cotinine (ng/mL).
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occurs leading to the formation of highly reactive intermediates that can
interact with the DNA (Curfs et al., 2004). Such effects of PAHs exposure
on plaque buildup in animals were found to be dose dependent (Penn
et al., 1981). Pre-clinical studies have also suggested that PAHs might
also exert their atherogenic effect via stimulation of an inflammatory
process involving an increased influx of proinflammatory cells into
these plaques (Curfs et al., 2005). The role of inflammation as a risk
factor for CVD development has been well established (Pearson et al.,
2003; Goff et al., 2013). Population based studies supported an associa-
tion between PAH and inflammation (Alshaarawy et al., 2013; Clark
et al., 2012). A recent study also suggested an association between
PAHs and a number of obesity-related cardiometabolic health risk fac-
tors (Ranjbar et al., 2015).
Several of the study limitations merit attention. Of main concern is
the cross sectional nature of NHANES which does not allow to draw
temporal or causal inferences regarding the association of PAHs and
CVD. In addition, our study does not have the data to estimate the
sources of exposure to PAHs. Urinary biomarker measurements reflect
recent PAH exposure as non-smoking sources of PAHs can vary day-
to-day in the general population. Finally, CVD was ascertained by self-
report. Accordingly, some recall bias may exist. However, these biases
are likely to be non-differential biases, which would minimize any
observed association. Notwithstanding these limitations, the study
findings are of interest because of the inclusion of a relatively large na-
tionally representative multiethnic sample, the NHANES standardized
data collection approaches, and the ability to adjust for potential
confounders.
In conclusion, this epidemiological evidence from the current
study tends to confirm what prior research found – namely, a posi-
tive association between PAH exposure and CVD. Any claim of ath-
erogenic effects of PAH exposure is premature, but given increased
prevalence of PAH exposure and CVD in the U.S. and elsewhere,
there is a reason to study their linkages. More probing experimenta-
tion of a clinical translational character is needed, including research
on potential mechanisms.
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Fig. 1.Model depicting the hypothesized PAH exposure-CVD association. Data for the National Health and Nutrition Examination Survey 2001–2010 (n= 7301)
Table 4
Estimated association of polycyclic aromatic hydrocarbon exposure on cardiovascular dis-
ease level in adults (≥20+ years), stratified by participant characteristics. Data for the
United States based on the National Health and Nutrition Examination Survey 2001–2010.
Characteristics Age-sex adjusteda
β (95% CI)
Multivariable adjustedb
β (95% CI)
Full sample 0.12 (0.07, 0.17) 0.12 (0.03, 0.20)
Sex
Male 0.06 (−0.01, 0.13) 0.08 (−0.02, 0.17)
Female 0.18 (0.11, 0.25) 0.16 (0.07, 0.26)
ESI
NH-White 0.13 (0.07, 0.19) 0.13 (0.03, 0.23)
NH-Black 0.10 (0.01, 0.19) 0.15 (0.04, 0.27)
Hispanic −0.04 (−0.12, 0.04) 0.01 (−0.10, 0.13)
Smoking
Never 0.08 (−0.04, 0.20) 0.11 (−0.01, 0.23)
Former 0.03 (−0.09, 0.15) 0.02 (−0.10, 0.14)
Recently active 0.24 (0.09, 0.39) 0.25 (0.13, 0.37)
A WLSMV estimator was used (probit regression are estimated). Model fit for each of the
three models: RMSEA b 0.05; CFI ≥ 0.95.
a Adjusted for age and sex, except for stratified variable.
b Adjusted for age, sex, ESI, education, PIR, alcohol drinking, serum cotinine, total cho-
lesterol and BMI, except for stratified variable.
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Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.envint.2016.02.006.
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Important Information for Users 
The Centers for Disease Control and Prevention (CDC) periodically refines these laboratory methods.  It is the 
responsibility of the user to contact the person listed on the title page of each write-up before using the analytical 
method to find out whether any changes have been made and what revisions, if any, have been incorporated.  
PAHs in Urine  
NHANES 2007-2008 
  
 
 
 
This document details the Lab Protocol for NHANES 2005–2006 data.  
 
A tabular list of the released analytes follows: 
 
 
Data File Name  Variable Name  SAS Label  
PAH_E 
URXPO1  1-napthol (ng/L)  
URXPO2  2-napthol  
URXPO3  3-fluorene  
URXPO4  2-fluorene  
URXPO5  3-phenanthrene  
URXPO6  1-phenanthrene  
URXPO7  2-phenanthrene  
URXP10  1-pyrene  
URXP17  9-fluorene  
  
 
 
  
1. Clinical Relevance and Summary of Test Principle 
 
a. Clinical Relevance 
 
Polycyclic aromatic hydrocarbons (PAHs) are a class of ubiquitous environmental 
contaminants formed during incomplete combustion processes. Many of them have 
been identified as suspected human carcinogens.  Common routes of occupational 
exposure may include work involving diesel fuels and coal tars such as paving and 
roofing.  Possible environmental exposures include smoking, diet, smog and forest 
fires.  Threshold levels for carcinogenicity have not been determined for most PAHs.  
Application of this method to analyze samples obtained from participants in the 
National Health and Nutrition Examination Survey (NHANES) will help determining 
the reference range of these chemicals in general U.S. population, aged 6 years and 
higher. 
 
b. Test Principle 
 
The specific analytes measured in this method are monohydroxy-PAH (OH-PAH).  
The procedure involves enzymatic hydrolysis of urine, extraction, derivatization and 
analysis using capillary gas chromatography combined with high resolution mass 
spectrometry (GC-HRMS).  This method uses isotope dilution with carbon-13 
labeled internal standards.  Ions from each analyte and each carbon-13 labeled 
internal standard are monitored, and the abundances of each ion are measured.  
The ratios of these ions are used as criteria for evaluating the data.  The analytes 
measured in this procedure are shown in Table 1.  By evaluating these analytes in 
urine, a measurement of the body burden from PAH exposure is obtained. 
 
Table 1. Analytes measured, their parent compounds, and their abbreviations.  
No. Parent PAH Metabolite/Analyte Abbreviation 
1 Naphthalene 1-hydroxynaphthalene 1-NAP 
2 Naphthalene 2-hydroxynaphthalene 2-NAP 
3 Fluorene 9-hydroxyfluorene 9-FLU 
4 Fluorene 2-hydroxyfluorene 2-FLU 
5 Fluorene 3-hydroxyfluorene 3-FLU 
6 Phenanthrene 1-hydroxyphenanthrene 1-PHE 
7 Phenanthrene 2-hydroxyphenanthrene 2-PHE 
8 Phenanthrene 3-hydroxyphenanthrene 3-PHE 
9 Phenanthrene 4-hydroxyphenanthrene 4-PHE 
10 Pyrene 1-hydroxypyrene 1-PYR 
 
2. Safety Precautions 
 
  
a. Reagent toxicity or carcinogenicity 
 
Some of the reagents necessary to perform this procedure are toxic.  Special care 
must be taken to avoid inhalation or dermal exposure to the reagents necessary to 
carry out the procedure. 
 
b. Radioactive hazards 
 
There are no radioactive hazards associated with this procedure. 
 
c. Microbiological hazards 
 
Although urine is generally regarded as less infectious than serum, the possibility of 
being exposed to various microbiological hazards exists.  Appropriate measures 
must be taken to avoid any direct contact with the specimen (See Section 2.e.). CDC 
recommends a Hepatitis B vaccination series and a baseline test for health care and 
laboratory workers who are exposed to human fluids and tissues.  Observe 
Universal Precautions. 
 
d. Mechanical hazards 
 
There are only minimal mechanical hazards when performing this procedure using 
standard safety practices.  Laboratory analysts must read and follow the 
manufacturer’s information regarding safe operation of the equipment.  Avoid direct 
contact with the mechanical and electronic components of the mass spectrometer 
unless all power to the instrument is off.  Generally, mechanical and electronic 
maintenance and repair must only be performed by qualified technicians.  The 
autosampler and the mass spectrometer contain a number of areas which are hot 
enough to cause burns.  Precautions must be used when working in these areas. 
 
e. Protective equipment 
 
Standard safety precautions must be followed when performing this procedure, 
including the use of a lab coat/disposable gown, safety glasses, appropriate gloves, 
and chemical fume hood.  Refer to the laboratory Chemical Hygiene Plan and CDC 
Division of Laboratory Sciences safety policies and procedures for details related to 
specific activities, reagents, or agents.        
 
f. Training 
 
Formal training in the use of a high resolution mass spectrometer is necessary.  
Users are required to read the operation manuals and must demonstrate safe 
techniques in performing the method. Anyone involved in sample preparation must 
be trained in for all sample preparation equipment, chemical handling, and have 
basic chemistry laboratory skills. 
 
g. Personal hygiene 
 
Follow Universal Precautions.  Care must be taken when handling chemicals or any 
biological specimen.  Routine use of gloves and proper hand washing must be 
  
practiced.  Refer to the laboratory Chemical Hygiene Plan and CDC Division of 
Laboratory Sciences safety policies and procedures for details related to specific 
activities, reagents, or agents. 
 
h. Disposal of wastes 
 
Waste materials must be disposed of in compliance with laboratory, federal, state, 
and local regulations.  Solvents and reagents must always be disposed of in an 
appropriate container clearly marked for waste products and temporarily stored in a 
chemical fume hood.  All disposable items that come in direct contact with the 
biological specimens are to be placed in a biohazard autoclave bag that must be 
kept in appropriate containers until sealed and autoclaved.  The unshielded needles, 
pipette tips and disposable syringes must be placed immediately into a sharps 
container and autoclaved when this container becomes full. Wipe down all surfaces 
with a freshly prepared bleach solution (a 10% dilution of commercial sodium 
hypochlorite (bleach) or equivalent) when work is finished.  Any non-disposable 
glassware or equipment that comes in contact with biological samples must be 
washed with bleach solution before reuse or disposal.  Any other non-disposable 
glassware must be washed and recycled or disposed in an appropriate manner. 
 
Observe Universal Precautions.  Dispose of all biological samples and diluted 
specimens in a brown glass bottle; disinfect the bio-hazardous material with bleach 
(10% in final volume), and dispose according to CDC/DLS guidelines for disposal of 
hazardous waste. Dispose all used disposable laboratory supplies (tubes, pipette tips, 
etc.) in an autoclave bag at the end of the analysis according to CDC/DLS guidelines 
for disposal of hazardous waste. 
 
3. Computerization; Data-System Management  
 
a. Software and knowledge requirements 
 
This method has been validated using the Thermo Finnigan GC/HRMS system 
controlled by XcaliburTM Software 1.3.  Analyte peaks are integrated by Quan 
Browser under XcaliburTM.  Results are exported from Quan Browser result files to 
Microsoft Excel files that are subsequently used for calculations. Final results are 
stored in Excel format.  Knowledge of and experience with these software packages 
(or their equivalent) is required to utilize and maintain the data management 
structure. 
 
b. Sample information 
 
Information pertaining to particular specimens is entered into the database either 
manually or electronically transferred.  The result file is transferred electronically into 
the database.  No personal identifiers are used, and all samples are referenced to a 
blind coded sample identifier. 
 
c. Data maintenance 
 
  
All sample and analytical data are checked prior to being entered into the MS Excel 
for transcription errors and overall validity.  The database is routinely backed up 
locally through the standard practices of the NCEH network.  The local area network 
manager must be contacted for emergency assistance. 
 
d. Information security 
  
Information security is managed at multiple levels.  The information management 
systems that contain the final reportable results are restricted through user ID and 
password security access. The computers and instrument systems that contain the 
raw and processed data files require specific knowledge of software manipulation 
techniques and physical location.  Site security is provided at multiple levels through 
restricted access to the individual laboratories, buildings, and site.  Confidentiality of 
results is protected by referencing results to blind coded sample IDs (no names or 
personal identifiers have used). 
 
4. Procedures for Collecting, Storing, and Handling Specimens; Criteria for 
Specimen Rejection 
 
a. Special instructions 
 
No special instructions such as fasting or special diets are required. 
 
b. Sample collection 
 
Urine specimens are collected from subjects in standard urine collection cups.  
Samples must be refrigerated as soon as possible, and must be transferred to 
specimen vials within 24 hours of collection.  A minimum of 5 milliliters of urine is 
collected and poured into sterile vials with screw-cap tops.  The specimens are then 
labeled, frozen immediately to -20 ºC, and stored on dry ice for shipping.  Special 
care must be taken in packing to protect vials from breakage during shipment.  All 
samples in long-term storage must be kept at -70 ºC until analysis. 
 
c. Sample handling 
 
Specimen handling conditions are outlined in the Division of Laboratory Science 
(DLS) protocol for urine collection and handling (copies available in branch, 
laboratory and special activities specimen handling offices).  Collection, transport, 
and special requirements are discussed in the division protocol.  In general, urine 
specimens must be transported and stored at frozen (< -10 ºC). Once received, they 
can be frozen at -70 ± 10 °C until time for analysis.  Portions of the sample that 
remain after analytical aliquots are withdrawn must be refrozen at -70 ± 10 °C.  
Samples are not compromised by repeated freeze and thaw cycles.   
 
d. Sample quantity 
 
The minimum amount of specimen required for analysis is 0.5 mL, with the optimal 
amount being 2.0 mL. 
 
e. Unacceptable specimens 
  
 
Specimens must be frozen at a minimum of -20 ± 5 °C when delivered to the lab. 
The minimum volume required is 0.5 mL.  If either of these criteria is violated, then 
specimen must be rejected. Specimens are also rejected if suspected of 
contamination due to improper collection procedures or devices.  Specimen 
characteristics that may compromise test results include contamination of urine by 
contact with dust, dirt, etc. from improper handling.  Samples with visible 
microbiological growth (e.g. mold, bacteria) must also be rejected.  In all cases, 
request a second urine specimen if available.  A description of reasons for each 
rejected sample must be recorded on the sample transfer sheet, such as low sample 
volume, leaking or damaged container. 
 
5. Procedures for Microscopic Examinations; Criteria for Rejecting Inadequately 
Prepared Slides 
 
Not applicable for this procedure. 
 
6. Preparation of Reagents, Calibration Materials, Control Materials, and all Other 
Materials; Equipment and Instrumentation 
 
a. Reagents and sources 
 
See Table 2. 
 
Table 2. Reagents and the respective manufacturers 
Reagent Manufacturers* 
organic de-ionized water (D.I. H2O) Prepared in house, CDC (Aqua Solutions, 
Inc.) 
β-glucuronidase/arylsulfatase, H-1, powder 
enzyme 
Sigma Chemical, St. Louis, MO 
pentane, hexane, acetonitrile, toluene, and 
methanol (ABSOLV grade) 
Tedia Company, Fairfield, OH 
glacial acetic acid Sigma Chemical, St. Louis, MO 
Fisher Scientific, Pittsburgh, PA 
Silver nitrate Fisher Scientific, Pittsburgh, PA 
Sigma Chemical, St. Louis, MO 
sodium acetate  Sigma Chemical, St. Louis, MO 
N-methyl-N-(trimethylsilyl)-
trifluoroacetamide (MSTFA) 
Sigma Chemical, St. Louis, MO 
argon, nitrogen Air Products and Chemicals, Allentown, PA 
13C6 3-PHE, 13C12 -PCB105, 13C6 1-NAP, 
13C6 2-NAP, 13C6 9-FLU 
Cambridge Isotope Laboratories, Andover, 
MA 
  
13C6 3-FLU, 13C6 1-PYR ChemSyn, Lenexa, KS 
13C6 3-FLU, 13C6 9-FLU, 13C6 2-PHE Los Alamos National Laboratory, Los 
Alamos, NM 
1-NAP, 2-NAP, 2-FLU, 3-FLU, 9-FLU, 1-
PYR 
Sigma-Aldrich Chemicals, St. Louis, MO 
1-PHE, 2-PHE, 3-PHE, 4-PHE Promochem, Wesel, Germany 
 
* Equivalent products from other manufacturers may be used. 
 
b. Preparation of Reagents 
 
1) Sodium Acetate Buffer solution (1 M, pH 5.5) 
 
Place 41 g sodium acetate powder in a 500-mL vitro bottle and add 
approximately 300 mL de-ionized water (D.I. H2O). Stir on a stir plate until 
sodium acetate is completely dissolved.  Fill flask to the 500 mL line with D.I. 
H2O.  Adjust the pH to 5.5 with glacial acetic acid. 
 
2) β-glucuronidase/arylsulfatase Enzyme/Buffer solution (10 mg enzyme/mL 
buffer) 
 
Weigh 0.5 g of β-glucuronidase/arylsulfatase, H-1, powder enzyme into a 60-
mL ASE glass vial. Add 50 mL of the pre-prepared sodium acetate buffer and 
cap the vial. Place vial on a rotating mixer at 40 rpm until the enzyme is 
completely dissolved. 
 
3) N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) 
 
Open the sealed vial containing MSTFA from the vendor and place the MSTFA 
solution in an amber screw-cap vial (2-mL).  Displace the air over the MSTFA 
with a gentle stream of argon. The MSTFA can be stored in the amber screw-
cap vial for up to 1 month.  To add MSTFA to multiple samples, use an 
Eppendorf repeator pipette with a 100-µL pipette tip, set the pipette volume at 
10 µL, and then withdraw 100 µL of MSTFA.  Discard the first two aliquots and 
the last aliquot of MSTFA (10 µL per aliquot), aliquot 10 µL into each of the 
sample vials.   
 
c. Preparation of Calibration Materials 
 
 
 
 
 
 
 
 
All standard preparations are based on gravimetric determination, not by volume. 
Therefore, the final actual concentrations have minor deviation from the target 
concentrations, e.g. target concentration for an individual stock solution is 100 
ng/uL; the actual concentration is 98.7 ng/uL. Actual calculated concentrations 
based on weight are used in all data calculation and processing.     
 All OH-PAH are light sensitive and precautions to minimize exposure to light must 
be taken, such as use of UV-filtered yellow light in lab areas where samples are 
handled. 
  
 
 
 
1) Stock Solutions of Individual Analytes (target concentrations: 100 ng/µL, 400 
ng/µL for 1- and 2-NAP) 
 
Approximately 5-10 mg of neat standard is weighed into a silanized screw cap 
amber vial.  Add 3 mL of acetonitrile into the vial and record the exact weight of 
the solvent.  Allow the OH-PAH to dissolve by gentle swirling or placing in an 
ultrasonic bath.  Dilute the individual standards using toluene to 100 ng/µL (400 
ng/µL for 1- and 2-NAP) with a final volume of 3.0 mL.  All solutions are stored 
in a refrigerator with an inert argon atmosphere in the vials.    
 
2) Working Standard Solution of 10 native OH-PAH mix (W.S.A) 
 
Combine 400 µL from each of the individual native OH-PAH standard stock 
solutions in a silanized screw cap amber vial to generate the working standard 
solution (W.S.A, target concentration at 4 ng/µL for each native OH-PAH 
concentration, except for 1- and 2-NAP at 16 ng/µL).  Homogenize the mixture 
by gentle swirling and vortexing.  Solutions of other concentrations may also be 
prepared, if needed. Displace air in the vial with argon, cap the vials, and 
stored them in a refrigerator until needed.   
 
3) Working Standard Solution of 10 C13-labeled OH-PAH mix (W.S.I) 
 
Combine individual 13C-labeled OH-PAH standard stock solutions (90 ng/µL) in 
a silanized screw cap amber vial to generate the working internal standard 
solution (W.S.I, target concentration at 6 ng/µL for each of the 10 13C-labeled 
OH-PAHs, except for C13-labeled 1- and 2-NAP at 24 ng/µL).  Homogenize the 
mixture by gentle swirling and vortexing.  Displace air in the vial with argon, cap 
the vials, and stored them in a refrigerator until needed. 
 
4) External Calibration Standards (E.C.S)  
 
External calibration standards (E.C.S.) are prepared as presented in Table 3 
below. Concentrations for 1- and 2-NAP in all standards are 4 times higher than 
the rest of the native compounds, because these two compounds are present 
in urine samples at high concentrations. Target concentrations for 13C-labled 
internal standards are 100 pg/µL (400 pg/µL for C13-labeled 1- and 2-NAP) in 
all calibration standards. 
 
In addition, due to high concentrations for 1- and 2-NAP often found in 
specimens, two additional calibration standards were prepared. The two 
calibration standards are at levels of 2000 and 4000 pg/µL (8000 and 16,000 
pg/µL for 1- and 2-NAP), and were used to evaluate and extend the linear 
range of the instrument calibration curves.   
 
Table 3. Preparation of external calibration standards (ECS)  
 
  
Standard 
No. 
Analytes, excluding 1- & 2-NAP 1- and 2- NAP 
Target 
concentration 
(pg/µL) 
Equivalent 
concentration in 
urine(pg/mL) 
Target 
concentration 
(pg/µL) 
Equivalent 
concentration in 
urine (pg/mL) 
1 1 5 4 20 
2 2 10 8 40 
3 5 25 20 100 
4 10 50 40 200 
5 50 250 200 1,000 
6 100 500 400 2,000 
7 500 2500 2,000 10,000 
8 1000 5,000 4,000 20,000 
 
5) Internal Qualification Standards (I.Q.S) 
 
Weigh in 4.167 mL of W.S.I into a 1-L silanized volumetric flask. Dilute the 
solution with acetonitrile to the 1-L line to get the internal qualification standard 
(I.Q.S).  The target concentration of each 13C-labeled OH-PAH is 25 pg/µL. 
Aliquot 1.9 mL of I.Q.S. into amber 2-mL standard vials, cap and seal the vials 
with Argon. Store all I.Q.S. vials in the fridge until use.  
 
6) Mass Spectrometric Check Solution 
 
This solution is used daily to monitor the operating performance of the GC 
column and the mass spectrometer.  A solution of 20 fg/µL of a tetra-
chlorinated dioxin is used as the check solution.  For a 1 µL injection, a 
minimum signal-to-noise of 4 on the m/z 321.894 peak must be obtained.   
 
d. Preparation of Control Materials 
 
1) Quality Control (QC) materials 
 
Prepare quality control materials by spiking a known amount of native OH-PAH 
mixture (in acentonitrile) into 2000 mL of an anonymous filtered urine pool (500 
pg/mL urine).  Homogenize the QC solutions overnight for equilibration.  On the 
next day aliquot the QC solutions into 16 x 100 mm test tubes (2 mL in each 
tube) and store them at -70 ± 10 °C until use.  
  
2) Recovery Spiking Solution (R.S.S) 
 
The recovery standard (13C12 PCB105) was purchased as a solution (40 
µg/mL, in nonane).  Dilute the standard solution using toluene to 100 pg/µL.  
This will be used as the recovery spiking solution (R.S.S.).  Aliquot 1.7 mL of 
E.R.S. into amber 2-mL standard vials, cap and seal the vials with Argon. Store 
all E.R.S. vials at 4 ± 5 °C until use. 
  
 
3) Proficiency Test Material (PT) 
 
Prepare quality control materials by spiking a known amount of W.S.A (at a 
different level as the QC) into 100 mL of an anonymous urine pool (filtered) to 
achieve the target concentration.  Prepare four urine pools at levels within the 
linear range of the method.  After spiking the urine pool with a known amount of 
W.S.A, homogenize the PT solutions overnight for equilibration.  On the next 
day aliquot the PT solutions into 16 x 100 mm test tubes (2 mL in each tube), 
the PT samples were then randomized by an external PT administrator, labeled 
by external lab technicians, and store them at -70 ± 10 °C until use.  
 
e. Other equipment, materials, and supplies 
 
Materials / supplies and sources used during the development, validation, and 
application of this method are listed below.  Materials / supplies procured from other 
sources must meet or exceed these specifications. 
 
• Gilson 215 liquid handler (Gilson Inc., Middleton, WI) 
• 818 Automix mixer (Gilson Inc., Middleton, WI) 
• Water bath/sonicator (Branson Ultrasonics, Danbury, CT) 
• TurboVap LV evaporator (Caliper LifeSciences, Hopkinton, MA) 
• Incubator ovens (Fisher Scientific) 
• pH meter (Thermo) 
• Microbalance (Mettler-Toledo) 
• Stirring/heating plates (Corning) 
• Miscellaneous glassware (Pyrex, Kimax, Wheaton or Corning) 
• Eppendorf Repeater Plus Pipette (Brinkmann Instruments Inc., Westbury, 
NY). 
• Rainin Electronic Pipettes (Rainin, California) 
• Pasteur pipettes and bulbs (VWR). 
• Maxi-mix Vortex mixer (Barnstead International) 
• Allegra-6 centrifuge (Beckman-Coulter) 
• Amber screw top vials with various volume (Supelco, Inc., Bellefonte, PA) 
• Clear autosampler vials, 0.5 mL (SunSri) 
 
f. Instrumentation  
 
The analyses are performed on a ThermoFinnigan MAT-95XL high resolution mass 
spectrometer (Finnigan MAT, San Jose, CA) equipped with an electron impact 
  
ionization and interfaced to an Agilent Technologies 6890 gas chromatograph (GC) 
system (Agilent Technologies, Palo Alto, CA) 
 
1) Gas chromatograph configuration 
 
Chromatographic separation is performed on an Agilent 6890 gas 
chromatograph fitted with a DB-5 30-m fused silica capillary column. The 
column ID is 0.25-mm and the film thickness is 0.25-micron (J&W, # 22-5022 or 
equivalent).  The temperature program lasts a total of 28 minutes. (See Table 4 
for GC configuration and Table 5 for the GC temperature program.) 
 
Table 4. GC configuration 
 
GC Parameter Setting 
Carrier gas Helium 
Constant flow rate 1 mL/minute 
GC purge flow rate 70 mL/minute 
GC saver time 5 minutes 
GC save flow rate 15 mL/minute 
Injection mode Splitless 
Injector purge delay 2 minutes 
Injector temperature 270 ºC 
 
Table 5. Typical GC temperature program. Slight modification might be 
required to accommodate separation variations on commercial GC 
columns. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2) High Resolution Mass spectrometer (HRMS) configuration 
 
Time 
(min.) 
Ramp 
(C/min) Temperature (ºC) 
0 0 95 
2 15 95 
6 5 155 
20 40 225 
22.4 0 320 
27.4 - 320 
  
Thermo Finnigan MAT 95XL HRMS configuration is presented in Table 6.  The 
mass spectrometer is operated under Multiple Ion Detection (MID) mode.  The 
masses used to quantify analytes are presented in Table 7. 
 
Table 6. Thermo Finnigan MAT 95XL HRMS configuration  
 
HRMS Parameter Setting 
Scan mode Multiple ion detection 
Ionization type Electron impact 
Ion polarity mode Positive  
Electron energy 45 eV 
Resolution 10,000 
Ion source 250 ºC 
Conversion dynode voltage Positive 
Electron multiplier voltage 1.45 – 2.25 kV (or 106 gain) 
 
Table 7. Analyte masses  
 
Analyte Molecular Ion 
[M.+] 
1-NAP, 2-NAP 216.0970 
2-FLU, 3-FLU, 9-FLU 254.1127 
1-PHE, 2-PHE, 3-PHE, 4-PHE 266.1127 
1-PYR 290.1127 
13C6 1-NAP, 13C6 1-NAP 222.1172 
13C6 2-FLU, 13C6 3-FLU, 13C6 9-FLU  260.1328 
13C4 4-PHE, 13C4 1-PHE 270.1263 
13C6 3-PHE, 13C6 2-PHE 272.1328 
13C6 1-PYR 272.1328 
 
 
7. Calibration and Calibration Verification 
 
a. Calibration of Mass Spectrometer 
 
Calibrate and tune the Finnigan MAT 95XL mass spectrometer using FC43 
(perfluorotributylamine) according to the instructions in the operator’s manual 
located next to the instrument.  After calibrated with 10,000 resolution and maximum 
  
sensitivity, the instrument is prepared for the analysis of OH-PAHs as described in 
Section 8. 
 
b. Creation of calibration curve  
 
1) Calculation data 
 
A linear log-log calibration curve, using eight ECS with concentration ranging 
from 1 to 1000 pg/µL, is generated using the log ratio of the peak area of the 
analyte to the labeled internal standard against the log ratio of the native 
analyte concentrations to those of the labeled internal standards.  The 
concentrations in ECS correspond to 5 - 5,000 pg/mL (20-20,000 pg/mL) levels 
in 2 mL urine.  For urine samples with concentrations higher than the 
calibration curve, the highest two standards (2000 & 4000 pg/ µL, 8,000 and 
16,000 pg/µL for 1-&2-NAP) are prepared to extend the calibration curve and to 
accurately quantify those samples.  
 
2) Evaluation of curve statistics 
 
The R-squared value of the curve must be equal to or greater than 0.990.  
Linearity of the standard curve must extend over the entire standard range.  
 
3) Use of the calibration curve 
 
The lowest point on the calibration curve is the lowest reportable level and the 
highest point is above the expected range of results.  The remainders of the 
points are distributed between these two extremes, with the majority of points in 
the concentration range where most unknowns fall. 
  
c. Calibration verification  
 
In order to verify that this calibration of this test system is accurate and stable 
throughout reportable range, a full calibration curve is run monthly.  Calculated 
concentration must be within 10% deviation from expected concentration.  
 
 
8. Procedure Operation Instructions; Calculations; Interpretation of Results 
 
An analytical run consists of two blanks, two QCs, and 16 unknown urine samples. 
 
a. Sample Preparation 
 
All samples are prepared in a laboratory with non-UV yellow fluorescent lights. 
 
1) Hydrolysis 
 
Allow urine samples and QCs to thaw and reach room temperature.  Aliquot 2 
mL of urine sample (or 2 mL of D.I. H2O as blank) into a 16x100 mm test tube.  
Add 1 mL of 1 M sodium acetate butter (pH = 5.5) containing β-Glucuronidase/ 
  
arylsulfatase enzyme from Helix pomatia (10 mg enzyme/1 mL buffer) into the 
test tube. Place the uncapped sample tubes on the Gilson 215 liquid handler 
(Gilson Inc., Middleton, WI) initiate the automated spiking procedure.  All 
samples are spiked with 40 µL of I.Q.S on the Gilson 215 liquid handler. Cap 
the test tubes and invert gently several times to mix well.  Place the samples in 
a 37 ± 2 ºC oven and incubate the sample overnight (~17-18 hours).     
 
2) Automated Liquid-Liquid Extraction 
 
Add D.I. water (2 mL) to all samples prior to using the Gilson 215 liquid handler 
(Gilson Inc., Middleton, WI) fitted with an 818 AutoMix for automation. Place the 
uncapped sample tubes in the Gilson 215 and initiate the extraction procedure. 
The automated procedure will add 20% toluene/80% pentane (5 mL) to each 
sample.  Manually cap the tubes then place back on the AutoMix to mix for 5 
minutes (20 rpm). Centrifuge samples at 2800 rpm on an AllegraTM 6 
centrifuge (Beckman Coulter Inc., Fullerton, CA) until clear separation can be 
seen between layers (~20-40 minutes). Uncap the tubes and return them to the 
Gilson 215 to resume automation.  The liquid handler probe will transfer the 
organic phase to clean 16x100 test tubes.  Repeat extraction a second time 
until a total of 10mL of organic phase is collected in each test tube. The urine 
sample test tubes are no longer needed and may be discarded.   
 
3) Evaporation 
 
Spike the extract with 10 µL dodecane and place in a TurboVap LV evaporator.  
Under a stream of N2 and in a 40 ºC water bath, evaporate the pentane fraction 
(~10-15 minutes).  Transfer the remaining extract volume (~2mL) to a second 
TurboVap LV evaporator warmed with an 80 ºC water bath. Evaporate extracts 
to ~10µL within 20-30 minutes.  Spike each sample tube with 20 µL toluene 
and 5 µL R.S.S., vortex for a few seconds, and then transfer the contents to an 
amber autosampler vial. 
 
4) Derivatization 
 
Add 10 µL of MSTFA into the GC vial and then displace the air in the vial with a 
gentle stream of argon.  Quickly screw a cap onto the vial.  Place the vials in an 
incubator or oven set at 60 ± 5 ºC for 30 minutes.  The samples are then ready 
for analysis on the mass spectrometer.   
 
b. Instrument and software setup for the GC/HRMS 
 
1) Preliminary MAT 95 system setup and performance check  
 
Turn on the MAT 95; inject 2 µL FC-43 into the reference inlet. In the TUNE 
window, adjust resolution between 9900 and 10100.  Perform a GC/HRMS 
analysis of the mass spectrometer check solution (2, 3, 7, 8-TCDD, 10 fg/µL, 
1 µL injection) and verify chromatographic resolution and peak intensity.  In the 
lab note book, record the signal to noise of the check compound. 
 
  
2) Final setup and operation  
 
a) Create the run sequence 
 
In the Xcalibur Sequence Setup window, create a sequence for the run 
using the template.  Make sure that the appropriate number of samples is 
loaded, the appropriate filenames are assigned, and the appropriate sample 
positions on the autosampler tray are included in the run sequence.  Make 
sure that the correct process method and instrument method are selected.  
The latter defines GC, MID, Autosampler, and ICL methods.  The methods 
used are listed in Table 8. 
 
Table 8. GC/HRMS methods 
 
Program Method 
Instrument  NHANES.met 
GC  NHANES.mcr 
MID  NHANES.mid 
Autosampler pah_1ul.mcs 
ICL  Sleep90.icl 7 
Process NHANES.pmd 
 
Filenames conform to the following format: PMYYNNN, KMYYNNN or 
JMYYNNN where P = PAH samples run on the MAT 95 instrument named 
as CASSI, K = PAH samples run on the MAT 95 instrument named as 
MIKE, J = PAH samples run on the MAT 95 instrument named as ICE; M = 
month (A = January, B = February, C = March, etc.); YY = year (04 = year 
2004), and NNN = run number for the month.  For example, the filename 
PB01012 corresponds to PAH-February-2001-sample #12 run on MAT 95 – 
CASSI, and KD02267 would correspond to PAH-April-2002-sample #267 
run on MAT 95 – MIKE. 
 
b) Start the sequence 
 
Click Run Sequence in the main menu under Action.  Verify the sequence 
set up and make sure the whole sequence instead of one single sample is 
selected to be run.  Click OK; the system will immediately start by turning 
green on the first sample to run. 
 
3) System standby 
 
To place the MAT 95 in standby mode, enter the command .bye at the ICL 
prompt.  This command turns off the accelerator, multiplier and dynode voltage, 
and vents the reference compound (FC-43).  To reactivate the MAT 95, enter 
.run 0.50 at the command prompt.  Add the reference compound and tune. 
 
  
c. Processing of data 
 
After the run sequence finishes, process all raw data files in the whole sequence 
using the “NHANES.pmd” process method after which the analyte peaks in data files 
are automatically integrated using the process method.  Visually review and 
manually correct if needed the integration of each peak in the QuanBrowser window 
of the Xcalibur software.  Save the reviewed result file, export it as a MS Excel file, 
and save the Excel file on the Q:\ share drive.  Perform all further calculations such 
as standard curve generation, QC analysis, blank analysis, limit-of-detection 
determination, unknown sample calculations, data distribution, etc. in MS Excel and 
in SAS.  Import final results and all supporting information into a RBase database 
located on the Q:\ share drive.    
 
d. Replacement and Periodic Maintenance of Key Components 
 
1) MAT 95 XL Mass Spectrometer 
 
Check cooling water level and temperature monthly 
Clean the ion volume or replace it monthly 
Clean the ion source or replace it annually 
Replace the calibration gas septum monthly 
Trained Thermo Finnigan technicians perform all other maintenance based on 
an annual schedule, or as needed 
 
2) Agilent 6890 GC 
 
Change the injection port liner and septum daily 
Clean the injection port, clean or replace the gold seal monthly 
Cut the GC column for ~10” monthly or as needed 
Replace the GC column at 1000 analyses or sooner 
Replace Helium tank when the pressure is below 500 psi. 
  
Note: Accelerate the above maintenance schedules if necessary. 
 
9. Reportable Range of Results 
 
The linear range of the standard calibration curves determines the highest and lowest 
analytical values of an analyte that are reportable.  The calibration verification of the 
method encompasses this reportable range.  However, urine samples with analytical 
data values exceeding the highest reportable limit may be re-extracted using a smaller 
volume and re-analyzed so that the result is in the reportable range. 
 
a. Linearity Limits 
 
Analytical standards were linear for all analytes through the range of concentrations 
evaluated.  The linear range for all analytes except 1-NAP and 2-NAP is 5 pg/mL to 
40,000 pg/mL.  Calibration curves for 1-NAP and 2-NAP are extended to 160,000 
ng/L, because their high concentrations detected from unknown samples.   
Therefore, the linear range for 1-NAP and 2-NAP were 20 pg/mL to 160,000 pg/mL.  
  
Urine samples whose concentrations exceed these ranges must be diluted and re-
analyzed using a smaller aliquot. 
 
b. Limit of Detection 
 
The limit of detection (LOD) for this method is defined as the greater LOD calculated 
by two methods: (i) in direct relation to method blanks prepared in parallel with the 
unknown samples, as 3 times the standard deviation of the method blanks, and (ii) 
according to the instrumental detection limit defined as the lowest point in the 
calibration curve (1 pg/uL, or 5 pg/mL in 2-mL urine samples) verified to give a signal 
with the S/N equal to or greater than 5. The detection limits determined for each 
analyte are evaluated periodically (e.g. every 6 months or after an NHANES cycle) 
based on observed blank levels over the period. Typical LODs are presented in 
Table 9 (updated after NHANES 2005-06). 
 
Table 9.  Limits of detection (LOD)  
 
Analyte LOD (pg/mL) 
1-NAP 48 
2-NAP 13 
9-FLU 5 
3-FLU 5 
2-FLU 5 
4-PHE 5 
3-PHE 5 
1-PHE 5 
2-PHE 5 
1-PYR 5 
 
c. Precision 
 
The precision of the method is reflected in the variance of quality control samples 
analyzed over time.  The mean and coefficients of variation (CV) of the 318 QC 
samples over the analysis of NHANES 2005-06 are listed in Table 10 below.  These 
QC samples were prepared over 6 months by two different analysts using two 
automated liquid handlers and two GC/HRMS instruments. 
 
Table 10.  Mean, standard deviation, and CV for QC samples. The parameters are QC 
pool specific.  
 
Analyte Mean (pg/mL) Stdev (pg/mL) CV (%) 
1-NAP 519 33 6.4% 
2-NAP 791 28 3.5% 
9-FLU 539 12 2.1% 
3-FLU 433 10 2.3% 
  
2-FLU 507 12 2.4% 
4-PHE 508 16 3.1% 
3-PHE 501 13 2.6% 
1-PHE 339 10 2.8% 
2-PHE 493 12 2.5% 
1-PYR 485 17 3.6% 
 
d. Analytical specificity 
 
The HRMS system provides excellent analytical specificity.  The analyte peaks are 
located in well defined regions of the chromatogram with no visible interferences and 
low background.  In addition, the retention time for the analytes relative to the 
isotope internal standards give additional confirmation of the presence of analytes in 
the sample.  
 
e. Accuracy 
 
Presently no established standard reference material (SRM) exists for OH-PAHs in 
human urine. Therefore, we cannot evaluate the accuracy of this method by 
analyzing an SRM and compare to its certified concentrations. Nonetheless, the 
usage of isotopically labeled internal standards can adjust for any deviates occurred 
on the OH-PAH analytes during sample preparation and instrumental analysis, and 
thus provide assurance on the accuracy of this method.   
 
10. Quality Assessment and Proficiency Testing 
 
a. Quality Assessment 
 
Quality assessment procedures follow standard practices6.  Daily experimental 
checks are made on the stability of the analytical system.   Blanks and standards, as 
well as QC materials, are added to each day's run sequence.  The blank and 
standard are analyzed at the beginning of each run to check the system for possible 
contamination or in the spiking solutions and/or reagents. Two QCs are prepared 
and analyzed with each run; their concentrations are compared with acceptance 
criteria to assure the proper operation of the analysis. Relative retention times are 
examined for the internal standard to ensure the choice of the correct 
chromatographic peak.  
 
b. Quality Control Procedures  
 
1) Establishing QC limits 
 
Quality control limits are established by characterizing assay precision with 
repetitive analyses of the QC pool.  Different variables are included in the 
analysis (e.g. different analysts and instruments) to capture realistic assay 
variation over time.  The mean, standard deviation, coefficient of variation, and 
confidence limits are calculated from this QC characterization data set.   
Individual quality control charts for the characterization runs are created, 
  
examined, and quality control limits are used to verify assay precision and 
accuracy on a daily basis.  QC characterization statistics for OH-PAH analytes 
in NHANES 2005-06 are listed in Table 11. The characterization statistics are 
pool specific. 
 
Table 11.  Sample QC Characterization Statistics. The data are QC pool specific.  
  
Analyte 
Mean - 3σ 
(pptr) 
Mean - 2σ 
(pptr) 
Mean 
(pptr) 
Mean + 2σ 
(pptr) 
Mean + 3σ 
(pptr) 
1-NAP 420 453 519 585 618 
2-NAP 707 735 791 847 875 
9-FLU 503 515 539 563 575 
3-FLU 403 413 433 453 463 
2-FLU 471 483 507 531 543 
4-PHE 460 476 508 540 556 
3-PHE 462 475 501 527 540 
1-PHE 309 319 339 359 369 
2-PHE 457 469 493 517 529 
1-PYR 434 451 485 519 536 
 
2) Quality Control evaluation  
 
After the completion of a run, the quality control limits are consulted to 
determine if the run is “in control”.  The quality control rules apply to the 
average of the beginning and ending analyses of each of the QC pools.  The 
quality control results are evaluated according to Westgard rules: 
 
If both of the QCs are within the 2σ limits, then accept the run. 
 
If one of two QC results is outside the 2σ limits, then apply the rules below and 
reject the run if any condition is met. 
 
Extreme outliner: the result is outside the characterization mean by more than 
4σ limit.  
13σ – Average of both QCs is outside of a 3σ limit. 
22σ –QC results from two consecutive runs are outside of 2σ limit on the same 
side of the mean. 
R4σ sequential –QC results from two consecutive runs are outside of 2σ limit 
on opposite sides of the mean. 
10x sequential – QC results from ten consecutive runs are on the same side of 
the mean. 
 
If the QC result for an analyte is declared “out of control”, the results of that 
analyte for all patient samples analyzed during that run are invalid for reporting. 
 
  
c. Proficiency Testing (PT) 
  
1) Scope of PT 
 
There are no established PT materials; currently we are the only laboratory 
running this essay.  Therefore, the proficiency testing (PT) scheme for this 
method is administered by an in-house PT coordinator.  Because no standard 
reference materials exist for urinary analysis of hydroxy-PAH levels, PT 
samples are prepared in-house by spiking a known amount of standard into a 
well characterized urine pool, and blink-coded by in-house PT coordinator.  
 
2) Frequency of PT 
 
Five samples of unknown PT concentrations are analyzed twice a year using 
the same method described for unknown samples.  The PT administrator will 
randomly select five of the PT materials for analysis.  A passing score is 
obtained if at least four of the five samples fall within the prescribed limits 
established beforehand.   
 
 
3) Documentation of PT 
 
Analytical PT results are reviewed by the analyst and laboratory supervisor, 
and then submitted to the in-house PT Coordinator.  The PT results are 
evaluated by the PT Coordinator; the analysis passes proficiency testing if at 
least four of the five sample results deviate < 20% from the known value.  All 
proficiency results shall be appropriately documented.  If the assay fails 
proficiency testing then the sample preparation and instrumentation are 
thoroughly examined to identify and correct the source of assay error.   
 
11. Remedial Action if Calibration or QC Systems Fail to Meet Acceptable Criteria 
 
If the calibration or QC systems fail to meet acceptable criteria, suspend all operations 
until the source or cause of failure is identified and corrected.  If the source of failure is 
easily identifiable, for instance, failure of the mass spectrometer or a pipetting error, the 
problem is immediately corrected.  Otherwise, prepare fresh reagents and clean the 
mass spectrometer system.  Before beginning another analytical run, re-analyze several 
QC materials (in the case of QC failure) or calibration standards (in the case of 
calibration failure).  After re-establishing calibration or quality control, resume analytical 
runs.  Document the QC failures, reviewed the cases with supervisor to determine 
source(s) of problem, and take measures to prevent re-occurrence of the same 
problem.  
 
12. Limitations of Method, Interfering Substances and Conditions 
 
This method is an isotope dilution mass spectrometry method, widely regarded as the 
definitive method for the measurement of organic toxicants in human body fluids.  By 
using high resolution mass spectrometry, most interference is eliminated.  Due to the 
matrix used in this procedure, occasional unknown interfering substances have been 
encountered.  If chromatographic interference with the internal standards occurs, reject 
  
that analysis.  If repeat analysis still results in an interference with the internal standard, 
the results for that analyte are not reportable. 
 
13. Reference Ranges (Normal Values) 
 
Population-based reference ranges were determined from a subset of National Health 
and Nutritional Survey (NHANES) 2003-2004 urine samples.  The reference values are 
presented in Table 12. 
 
Table 12.  Reference values from NHANES 2003-2004  
 
Analyte 
Reference range concentrations 
Fresh weight (ng/L)  Creatinine adjusted (ng/g crea) 
50th  75th  90th  95th   50th  75th  90th  95th  
1-NAP 2260 7660 18500 26100  2100 6560 15100 21800 
2-NAP 2960 7500 17300 25800  2560 6340 14100 19900 
2-FLU 280 679 1850 2670  221 495 1510 2070 
3-FLU 103 302 1090 1740  86.6 256 856 1330 
9-FLU 269 541 929 1390  233 412 729 1100 
1-PHE 166 287 464 625  141 222 352 487 
2-PHE 62.2 117 206 291  52.3 85.8 150 212 
3-PHE 118 219 424 647  99.5 172 321 497 
4-PHE 25.9 53.7 96.8 152      
1-PYR 91.3 189 389 569  79.9 149 279 424 
 
14. Critical Call Results (“Panic Values”) 
 
It is unlikely that any result would be a "critical call", which would only be observed in 
acute poisonings.  There are no established “critical call” values.  Application of this 
method to NHANES studies will assist in determining levels of OH-PAH normally found 
in healthy US populations.  Test results in this laboratory are reported in support of 
epidemiological studies, not clinical assessments.  Data will help determine critical 
exposures. 
 
15. Specimen Storage and Handling During Testing 
 
Urine specimens may reach and maintain ambient temperature during analysis.  The 
urine extracts are stored in GC vials in a -70 ºC freezer after analysis.  Current studies 
indicate (CDC data) that the extracts are stable for three weeks. 
 
16. Alternate Methods for Performing Test or Storing Specimens if Test System  Fails   
 
Alternate validated methods have not been evaluated for measuring OH-PAH in urine.  
If the analytical system fails, then samples must be refrigerated (at 4 ± 3 oC) until the 
analytical system is restored to functionality.  If long-term interruption (greater that 4 
weeks) is anticipated, then store urine specimens at -70 ± 10 oC. 
 
  
The method is designed to run on a GC/HRMS instrument, and is not generally 
transferable to other instrumentation.  If the system fails, then samples must be 
refrigerated (at 4 ± 3 oC) until the analytical system is restored to functionality.  If long-
term interruption (greater that 4 weeks) is anticipated, then store urine specimens at -70 
± 10 oC.  Sample extracts in GC vials may be refrigerated for as long as three weeks.  If 
long-term interruption is anticipated, store sample extracts at -70 ± 10 oC. 
 
17. Test Result Reporting System; Protocol for Reporting Critical Calls (if Applicable)  
 
Study subject data is reported in both concentration units (ng/L) and adjusted based on 
creatinine excretion (µg/g creatinine). 
 
Once the validity of the data is established by the QC/QA system outlined above, these 
results are verified by a DLS statistician, and the data reported in both hard copy and 
electronic copy.  This data, a cover letter, and a table of method specifications and 
reference range values will be routed through the appropriate channels for approval (i.e. 
supervisor, branch chief, division director) as outlined in the DLS policy and procedure 
manual.  After approval at the division level, the report will be sent to the contact person 
who requested the analyses. 
  
18. Transfer or Referral of Specimens; Procedures for Specimen Accountability and 
Tracking 
 
If greater than 1 mL of sample remains following successful completion of analysis, this 
material must be returned to storage at -70 ± 10 °C in case reanalysis is required. 
These samples shall be retained until valid results have been obtained and reported 
and sufficient time has passed for review of the results. 
 
Standard record keeping (e.g., database, notebooks, and data files) is used to track 
specimens.  Specimens will only be transferred or referred to other DLS Branch 
laboratories or, if required, to CLIA certified laboratories.  Transfer is carried out through 
the DLS Samples Logistic Group.  Specimens may be stored at CDC specimen 
handling and storage facility (CASPIR). 
 
 
19.  Summary Statistics and QC Graphs 
 
  See following pages.
Summary Statistics for 1-naphthol 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
Lot001 102 19APR11 22SEP11 1657.04 51.43 3.1 
 
 
 
Summary Statistics for 1-phenanthrene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
Lot001 107 19APR11 22SEP11 356.33 11.72 3.3 
 
 
 
Summary Statistics for 1-pyrene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
Lot001 106 19APR11 22SEP11 561.19 21.20 3.8 
 
 
 
Summary Statistics for 2-fluorene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
Lot001 106 19APR11 22SEP11 567.74 9.33 1.6 
 
 
 
Summary Statistics for 2-naphthol 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
Lot001 104 19APR11 22SEP11 1744.88 52.46 3.0 
 
 
 
Summary Statistics for 2-phenanthrene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
Lot001 106 19APR11 22SEP11 507.80 11.38 2.2 
 
 
 
Summary Statistics for 3-fluorene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
Lot001 106 19APR11 22SEP11 472.50 8.51 1.8 
 
 
 
Summary Statistics for 3-phenanthrene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
Lot001 107 19APR11 22SEP11 515.40 12.14 2.4 
 
 
 
Summary Statistics for 9-fluorene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
Lot001 107 19APR11 22SEP11 633.52 10.40 1.6 
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Important Information for Users 
The Centers for Disease Control and Prevention (CDC) periodically refines these laboratory methods.  It is the 
responsibility of the user to contact the person listed on the title page of each write-up before using the analytical 
method to find out whether any changes have been made and what revisions, if any, have been incorporated.  
  
 
 
This document details the Lab Protocol for NHANES 2009–2010 data. 
A tabular list of the released analytes follows: 
 
 
Data File Name 
 
Variable Name 
 
SAS Label 
 
 
 
 
 
 
 
 
 
 
 
 
PAH_F 
 
URXPO1 
 
1-napthol(ng/L) 
 
URXPO2 
 
2-napthol(ng/L) 
 
URXPO3 
 
3-fluorene(ng/L) 
 
URXPO4 
 
2-fluorene(ng/L) 
 
URXPO5 
 
3-phenanthrene(ng/L) 
 
URXPO6 
 
1-phenanthrene(ng/L) 
 
URXPO7 
 
2-phenanthrene(ng/L) 
 
URXP10 
 
1-pyrene(ng/L) 
 
URXP17 
 
9-fluorene(ng/L) 
URXP19 4-phenanthrene (ng/L)            
OH-PAH in Urine    
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1. Clinical Relevance and Summary of Test Principle 
 
a. Clinical Relevance 
 
Polycyclic aromatic hydrocarbons (PAHs) are a class of ubiquitous environmental 
contaminants formed during incomplete combustion processes. Many of them have 
been identified as suspected human carcinogens (1), but threshold levels for 
carcinogenicity have not been determined for most PAHs. Occupational exposure 
may occur through work involving diesel fuels and coal tars such as paving and 
roofing.  Possible environmental exposures include smoking, diet, smog and forest 
fires (2, 3).  Because of potential widespread human exposure and potential risk to 
health, biomonitoring of PAHs is relevant for environmental public health. Application 
of this biomonitoring method to analyze samples obtained from participants in the 
National Health and Nutrition Examination Survey (NHANES) will help determine 
reference ranges for these chemicals in the general U.S. population, aged 6 years 
and older. 
 
b. Test Principle 
 
The specific analytes measured in this method are monohydroxylated metabolites of 
PAHs (OH-PAHs).  This procedure involves enzymatic hydrolysis of 
glucuronidated/sulfated OH-PAH metabolites in urine, extraction, derivatization and 
analysis using isotope dilution capillary gas chromatography tandem mass 
spectrometry (GC-MS/MS) (4, 5).  Ion transitions specific to each analyte and 
carbon-13 labeled internal standards are monitored, and the abundances of each ion 
are measured.  The analytes measured in this procedure are shown in Table 1.  
 
Table 1. Analytes measured their parent compounds, and their abbreviations.  
No. Metabolite/Analyte Parent PAH Abbreviation 
1 1-hydroxynaphthalene Naphthalene 1-NAP 
2 2-hydroxynaphthalene Naphthalene 2-NAP 
3 9-hydroxyfluorene Fluorene 9-FLU 
4 2-hydroxyfluorene Fluorene 2-FLU 
5 3-hydroxyfluorene Fluorene 3-FLU 
6 1-hydroxyphenanthrene Phenanthrene 1-PHE 
7 2-hydroxyphenanthrene Phenanthrene 2-PHE 
8 3-hydroxyphenanthrene Phenanthrene 3-PHE 
9 4-hydroxyphenanthrene Phenanthrene 4-PHE 
10 1-hydroxypyrene Pyrene 1-PYR 
OH-PAH in Urine    
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2. Safety Precautions 
 
a. Reagent Toxicity or Carcinogenicity 
 
Some of the reagents needed to perform this procedure are toxic.  Special care must 
be taken to avoid inhalation or dermal exposure to these reagents.  
 
β-Glucuronidase is a known sensitizer.  Prolonged or repeated exposure to the 
sensitizer may cause allergic reactions in certain sensitive individuals.   
 
Note: Material Safety Data Sheets (MSDS) for the chemicals and solvents used in 
this procedure can be found at http://www.msdsxchange.com/english/index.cfm. 
Laboratory personnel are advised to review the MSDS before using chemicals. 
 
b. Radioactive Hazards 
 
There are no radioactive hazards associated with this procedure. 
 
c. Microbiological Hazards 
 
Although urine is generally regarded as less infectious than serum, the possibility of 
being exposed to various microbiological hazards exists.  Appropriate measures 
must be taken to avoid any direct contact with the specimen (See Section 2.e.). CDC 
recommends a Hepatitis B vaccination series and a baseline test for health care and 
laboratory workers who are exposed to human fluids and tissues.  Observe 
Universal Precautions. Also, laboratory personnel handling human fluids and tissues 
are required to take the “Blood borne Pathogens Training” course offered at CDC to 
insure proper compliance with CDC safe work place requirements. 
 
d. Mechanical Hazards 
 
There are only minimal mechanical hazards when performing this procedure using 
standard safety practices.  Laboratory analysts must read and follow the 
manufacturer’s information regarding safe operation of the equipment.  Avoid direct 
contact with the mechanical and electronic components of the mass spectrometer 
unless all power to the instrument is off.  Generally, mechanical and electronic 
maintenance and repair must only be performed by qualified technicians.  The 
autosampler and the mass spectrometer contain a number of areas which are hot 
enough to cause burns.  Precautions must be used when working in these areas. 
 
e. Protective Equipment 
 
Standard safety precautions must be followed when performing this procedure, 
including the use of a lab coat/disposable gown, safety glasses, appropriate gloves, 
and chemical fume hood.  Refer to the laboratory Chemical Hygiene Plan and CDC 
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Division of Laboratory Sciences safety policies and procedures for details related to 
specific activities, reagents, or agents.        
 
f. Training 
 
Formal training in the use of a GC/MS-MS is necessary.  Users are required to read 
the operation manuals and must demonstrate safe techniques in performing the 
method.  Laboratorians involved in sample preparation must be trained for all 
sample preparation equipment, chemical handling, and have basic chemistry 
laboratory skills. 
 
g. Personal Hygiene 
 
Follow Universal Precautions.  Care must be taken when handling chemicals or any 
biological specimen.  Routine use of gloves and proper hand washing must be 
practiced.  Refer to the laboratory Chemical Hygiene Plan and CDC Division of 
Laboratory Sciences safety policies and procedures for details related to specific 
activities, reagents, or agents. 
 
h. Disposal of Wastes 
 
Waste materials must be disposed of in compliance with laboratory, federal, state, 
and local regulations.  Solvents and reagents must always be disposed of in an 
appropriate container clearly marked for waste products and temporarily stored in a 
chemical fume hood.  All disposable items that come in direct contact with the 
biological specimens are to be placed in a biohazard autoclave bag that must be 
kept in appropriate containers until sealed and autoclaved.  Unshielded needles, 
pipette tips and disposable syringes must be placed immediately into a sharps 
container and autoclaved when this container becomes full. Wipe down all surfaces 
with a freshly prepared bleach solution (a 10% dilution of commercial sodium 
hypochlorite (bleach) or equivalent) when work is finished.  Any non-disposable 
glassware or equipment that comes in contact with biological samples must be 
washed with bleach solution before reuse or disposal.  Any other non-disposable 
glassware must be washed and recycled or disposed in an appropriate manner. To 
insure proper compliance with CDC requirements, laboratory personnel are required 
to take annual hazardous waste disposal training courses. 
 
Observe Universal Precautions.  Dispose of all biological samples and diluted 
specimens in a brown glass bottle; disinfect the bio-hazardous material with 
bleach (10% in final volume), and dispose according to CDC/DLS guidelines for 
disposal of hazardous waste. Dispose all used disposable laboratory supplies 
(tubes, pipette tips, etc.) in an autoclave bag at the end of the analysis 
according to CDC/DLS guidelines for disposal of hazardous waste. 
 
 
3. Computerization; Data-System Management  
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a. Software and Knowledge Requirements 
 
This method has been validated using the Agilent GC/QQQ 7000 GC-MS/MS 
system controlled by Agilent MassHunter WorkstationTM software.  Analyte 
chromatographic peaks are integrated by Quantitative Analysis under 
MassHunterTM.  Results are exported from MassHunter result files to Microsoft Excel 
files that are subsequently used for calculations. Final results are processed using 
SAS and stored in both Excel and SAS format.  Knowledge of and experience with 
these software packages (or their equivalent) is required to utilize and maintain the 
data management structure. 
 
b. Sample Information 
 
Information pertaining to particular specimens is entered into the database either 
manually or electronically transferred.  The result file is transferred electronically into 
the database.  No personal identifiers are used, and all samples are referenced to a 
blind coded sample identifier. 
 
c. Data Maintenance 
 
All sample and analytical data are checked in MS Excel and SAS for overall validity.  
The database is routinely backed up locally through the standard practices of the 
CDC network.  The local area network manager must be contacted for emergency 
assistance. 
 
d. Information Security 
  
Information security is managed at multiple levels.  The information management 
systems that contain the final reportable results are restricted through user ID and 
password security access. The computers and instrument systems that contain the 
raw and processed data files require specific knowledge of software manipulation 
techniques and physical location.  Site security is provided at multiple levels through 
restricted access to the individual laboratories, buildings, and site.  Confidentiality of 
results is protected by referencing results to blind coded sample IDs (no names or 
personal identifiers are used). 
 
 
4. Procedures for Collecting, Storing, and Handling Specimens; Criteria for 
Specimen Rejection 
 
a. Special Instructions 
 
No special instructions such as fasting or special diets are required. 
 
b. Sample Collection 
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Urine specimens are collected from subjects in standard urine collection cups.  
Samples should be refrigerated as soon as possible, and preferably transferred to 
specimen vials within 24 hours of collection.  If at all possible, a minimum of 5 
milliliters of urine is collected and poured into sterile polypropylene or glass vials with 
screw-cap tops.  The specimens should be labeled, frozen at or below -20 ºC, and 
stored on dry ice for shipping.  Special care must be taken in packing to protect vials 
from breakage during shipment.  All samples in long-term storage must be kept 
frozen, preferably at -70 ºC, until analysis. 
 
c. Sample Handling 
 
Specimen handling conditions are outlined in the Division of Laboratory Sciences 
(DLS) protocol for urine collection and handling (copies available in branch, 
laboratory and special activities specimen handling offices).  Collection, transport, 
and special requirements are discussed in the division protocol.  In general, urine 
specimens should be transported and stored frozen. Once received, they should be 
frozen, preferably at -70 °C, until time for analysis.  Portions of the sample that 
remain after analytical aliquots are withdrawn must be refrozen as soon as possible 
after analysis.     
 
d. Sample Quantity 
 
The regular sample size for analysis is 1.0 mL, and the minimum amount of 
specimen required for analysis is 20 µL. 
 
e. Unacceptable Specimens 
 
Specimens must be frozen when delivered to the lab. The minimum volume required 
is 0.2 mL.  If either of these criteria is violated, then specimen would be rejected. 
Specimens are also rejected if suspected of contamination due to improper 
collection procedures or devices.  Specimen characteristics that may compromise 
test results include contamination of urine from improper handling.  Samples with 
visible microbiological growth (e.g. mold, bacteria) must also be rejected.  In all 
cases, request a second urine specimen if available.  A description of reasons for 
each rejected sample must be recorded on the sample transfer sheet, such as low 
sample volume, leaking or damaged container. 
 
 
5. Procedures for Microscopic Examinations; Criteria for Rejecting Inadequately 
Prepared Slides 
 
Not applicable for this procedure. 
 
 
6. Preparation of Reagents, Calibration Materials, Control Materials, and all Other 
Materials; Equipment and Instrumentation 
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a. Reagents and Sources 
 
See Table 2. 
 
Table 2. Reagents and the respective manufacturers 
Reagent Manufacturers* 
de-ionized water (D.I. H2O) Prepared in house, CDC (Aqua 
Solutions, Inc.) 
β-glucuronidase/arylsulfatase (H-1, 
powder enzyme), glacial acetic acid, 
sodium acetate, N-methyl-N-
(trimethylsilyl)-trifluoroacetamide 
(MSTFA) 
Sigma Chemical, St. Louis, MO 
pentane, hexane, acetonitrile, toluene, 
and methanol (ABSOLV grade) 
Tedia Company, Fairfield, OH 
argon, nitrogen Air Products and Chemicals, 
Allentown, PA 
13C6 3-PHE, 13C12 -PCB105, 13C6 1-
NAP, 13C6 2-NAP, 13C6 9-FLUO  
Cambridge Isotope Laboratories, 
Andover, MA 
13C6 3-FLU, 13C6 1-PYR ChemSyn, Lenexa, KS 
13C6 3-FLU, 13C6 9-FLU, 13C6 2-PHE Los Alamos National Laboratory, 
Los Alamos, NM 
1-NAP, 2-NAP, 2-FLU, 3-FLU, 9-FLU, 1-
PYR 
Sigma-Aldrich Chemicals, St. Louis, 
MO 
1-PHE, 2-PHE, 3-PHE, 4-PHE Promochem, Wesel, Germany 
* Equivalent products from other manufacturers may be used. 
 
b. Preparation of Reagents 
 
1) Sodium Acetate Buffer Solution (1 M, pH 5.5) 
 
Place 41 g sodium acetate powder in a 500-mL vitro bottle and add 
approximately 300 mL de-ionized water (D.I. H2O). Stir on a stir plate until 
sodium acetate is completely dissolved.  Fill flask to the 500 mL line with D.I. 
H2O.  Adjust the pH to 5.5 with glacial acetic acid.  
 
2) β-glucuronidase/arylsulfatase Enzyme/Buffer solution  
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Weigh 0.5 g of β-glucuronidase/arylsulfatase, H-1, powder enzyme into a 60-
mL ASE glass vial. Add 50 mL of the pre-prepared sodium acetate buffer and 
cap the vial. Place vial on a rotating mixer at 40 rpm until the enzyme is 
completely dissolved. 
 
3) Ascorbic Acid Solution   
 
Weigh 1.25g of L-ascorbic acid into a 20mL borosilicate glass vial. Add 5.0mL 
of the deionized water and cap the vial. Place vial on a rotating mixer at 40 rpm 
until the solute is completely dissolved. 
 
4) N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) 
 
Open the sealed vial containing MSTFA from the vendor and place the MSTFA 
solution in an amber screw-cap vial (2-mL).  Displace the air over the MSTFA 
with a gentle stream of argon. The MSTFA can be stored in the amber screw-
cap vial for up to 1 month.  To add MSTFA to multiple samples, use an 
Eppendorf repeater pipette with a 100-µL pipette tip, set the pipette volume at 
10 µL, and then withdraw 100 µL of MSTFA.  Discard the first two aliquots and 
the last aliquot of MSTFA (10 µL per aliquot), aliquot 10 µL into each of the 
sample vials.   
 
c. Preparation of Calibration Materials 
 
1) Stock Solutions of Individual Analytes (target concentration: 400 ng/µL for 1- 
and 2-NAP, 100 ng/µL for remaining analytes) 
 
Approximately 5-10 mg of neat standard is weighed into a silanized screw cap 
amber vial.  Add 3 mL of acetonitrile into the vial and record the exact weight of 
the solvent.  Allow the standards to dissolve by gentle swirling or placing in an 
ultrasonic bath.  Dilute the individual standards using toluene to 100 ng/µL (400 
ng/µL for 1- and 2-NAP) with a final volume of 3.0 mL.  All solutions are stored 
in a refrigerator with an inert argon atmosphere in the vials.    
 
2) Working Standard Solution of Native Standard Mix (W.S.A) 
 
Combine 400 µL from each of the individual native standard stock solutions in a 
silicanized screw cap amber vial to generate the working standard solution 
(W.S.A, target concentration: 4 ng/µL for each native compound concentration, 
except for 1- and 2-NAP at 16 ng/µL).  Homogenize the mixture by gentle 
swirling and vortexing.  Solutions of other concentrations may also be 
prepared, if needed. Displace air in the vial with argon, cap the vials, and store 
them in a refrigerator until needed.   
 
3) Working Standard Solution of  13C-labeled Standard Mix (W.S.I) 
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Combine individual 13C-labeled standard stock solutions (90 ng/µL) in a 
silicanized screw cap amber vial to generate the working internal standard 
solution (W.S.I, target concentration: 6 ng/µL for each of the 13C-labeled 
compounds, except for 13C-labeled 1- and 2-NAP at 24 ng/µL ).  Homogenize 
the mixture by gentle swirling and vortexing.  Displace air in the vial with argon, 
cap the vials, and store them in a refrigerator until needed. 
 
4) External Calibration Standards (E.C.S)  
 
A typical set of external calibration standards (E.C.S.) are prepared as 
presented in Table 3 below. The preparation of standards is done by 
gravimetric determination. Therefore, the exact concentration for each standard 
will slightly deviate from the target concentration listed in Table 3. 
Concentrations for 1- and 2-NAP in all standards are 4 times higher than the 
rest of the native compounds because these two compounds are present in 
urine samples at higher concentrations. Target concentrations for 13C-labeled 
internal standards are 100 pg/µL (400 pg/µL for 13C-labeled 1- and 2-NAP) in 
all calibration standards.  
 
In addition, due to higher concentrations of 1- and 2-NAP often found in 
specimens, two additional calibration standards are prepared for 1-NAP and 2-
NAP. The two calibration standards are at levels of 8000 and 16,000 pg/µL and 
only contain 1- and 2-NAP. These two calibration standards are used to 
evaluate and extend the linear range of the instrument calibration curves.   
 
Table 3. Preparation of external calibration standards (ECS)  
 
Standard 
No. 
Analytes, excluding 1- & 2-
NAP 1- and 2- NAP 
Target 
concentration 
(pg/μL) 
Equivalent 
concentration 
in urine 
(pg/mL) 
Target 
concentration 
(pg/μL) 
Equivalent 
concentration 
in urine 
(pg/mL) 
1 1 10 4 40 
2 2 20 8 80 
3 5 50 20 200 
4 10 100 40 400 
5 50 500 200 2,000 
6 100 1000 400 4,000 
7 500 5000 2,000 20,000 
8 1000 10,000 4,000 40,000 
9 n/a n/a 8,000 80,000 
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10 n/a n/a 16,000 160,000 
 
5) Internal Qualification Standards (I.Q.S) 
 
Weigh in 4.167 mL of W.S.I into a 1-L silanized volumetric flask. Dilute the 
solution with acetonitrile to the 1-L line to get the internal qualification standard 
(I.Q.S).  The concentration of each 13C-labeled IS 25 pg/µL. Aliquot 1.9 mL of 
I.Q.S. into amber 2-mL standard vials, cap and seal the vials with argon. Store 
all I.Q.S. vials in the fridge until use.  
 
d. Preparation of Control Materials 
 
1) Quality Control (QC) Materials 
 
Prepare quality control materials by spiking a known amount of native standard 
mixture (in acetonitrile) into 2000 mL of an anonymous filtered urine pool (300 
pg/mL for QCL, 800 pg/mL for QCH).  Homogenize the QC solutions overnight 
for equilibration.  On the next day aliquot the QC solutions into 16 x 100 mm 
test tubes and store them at -70 °C until use.  
  
2) Recovery Spiking Solution (R.S.S) 
 
The recovery standard (13C12 PCB105) was purchased as a solution (40 
µg/mL, in nonane).  Dilute the standard solution using toluene to 100 pg/µL.  
This will be used as the recovery spiking solution (R.S.S.).  Aliquot 1.7 mL of 
E.R.S. into amber 2-mL standard vials, cap and seal the vials with argon. Store 
all E.R.S. vials at 4 °C until use. 
 
3) Proficiency Test Material (PT) 
 
Prepare quality control materials by spiking a known amount of W.S.A (at a 
different level as the QC) into 100 mL of an anonymous urine pool (filtered) to 
achieve the target concentration.  Prepare four urine pools at levels within the 
linear range of the method.  After spiking the urine pool with a known amount of 
W.S.A, homogenize the PT solutions overnight for equilibration.  On the next 
day aliquot the PT solutions into 16 x 100 mm test tubes (2 mL in each tube). 
PT samples are then randomized by an external PT administrator, labeled by 
external lab technicians, and stored at -70 °C until use.  
 
 
e. Other Equipment, Materials, and Supplies 
 
Materials / supplies and sources, or their equivalent, used during the development, 
validation, and application of this method are listed below.   
 
• Gilson 215 liquid handler (Gilson Inc., Middleton, WI) 
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• 818 Automix mixer (Gilson Inc., Middleton, WI) 
• Water bath/sonicator (Branson Ultrasonics, Danbury, CT) 
• RapidVap evaporator (Labconco, Kansas City, MO) 
• Incubator ovens (Fisher Scientific) 
• pH meter (Thermo) 
• Microbalance (Mettler-Toledo) 
• Stirring/heating plates (Corning) 
• Miscellaneous glassware (Pyrex, Kimax, Wheaton or Corning) 
• Eppendorf Repeater Plus Pipette (Brinkmann Instruments Inc., Westbury, 
NY). 
• Rainin Electronic Pipettes (Rainin, California) 
• Maxi-mix Vortex mixer (Barnstead International) 
• Allegra-6 centrifuge (Beckman-Coulter) 
• Amber screw top vials with various volume (Supelco, Inc., Bellefonte, PA) 
• Amber autosampler vials, 350 µL (National Scientific) 
 
f. Instrumentation  
 
The analyses are performed on an Agilent 7000A tandem mass spectrometer 
(Agilent Technologies, Santa Clara, CA) equipped with an electron ionization ion 
source and interfaced to an Agilent 7890A gas chromatograph (Agilent 
Technologies, Santa Clara, CA). 
 
1) Gas Chromatograph Configuration 
 
Chromatographic separation is performed on an Agilent 7890A GC fitted with a 
ZB-5MS (Phenomenex or equivalent) 30-m fused silica capillary column. The 
column ID is 0.25-mm and the film thickness is 0.25-micron.  The temperature 
program runs a total of 22 minutes. (See Table 4 for GC configuration and 
Table 5 for a typical GC temperature program.)  
 
Table 4. GC configuration 
 
GC Parameter Setting 
Carrier gas Helium 
Constant flow rate 0.9 mL/min 
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GC septum purge flow rate 3 mL/min 
GC gas saver after 3 min 
GC gas saver flow rate 20 mL/min 
Injection mode Pulsed Splitless 
Injection pulse pressure 25 psi until 0.4 min 
Injector temperature 270 ºC 
 
 
Table 5. Typical GC temperature program. Slight modifications might be 
required to accommodate separation variations on commercial GC 
columns. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2) Tandem Mass Spectrometer (MS/MS) Configuration 
 
The Agilent 7000A MS/MS configuration is presented in Table 6.  The mass 
spectrometer is operated under multiple reaction monitoring (MRM) mode.  The 
ion transitions used to quantify analytes are presented in Table 7. 
 
 
 
 
Table 6. Thermo TSQ Quantum MS/MS configuration  
 
MS/MS Parameter Setting 
Scan mode Multiple reaction monitoring 
Ionization type Electron ionization 
Time (min.) Ramp (C/min) Temperature (ºC) 
0 0 95 
1.00 15 195 
7.67 2 206 
13.2 0 206 
16.2 40 320 
19.0 0 320 
22.0 - 320 
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MS/MS Parameter Setting 
Ion polarity mode Positive  
Electron energy -70 eV 
Emission current 35 µA 
Ion source temperature 270 ºC 
Electron multiplier voltage operated at GAIN + 100 
 
 
 
Table 7. Analyte MS/MS Ion Transitions.  
 
Analyte Ion transition CE (eV) 
1-NAP 216.1 → 185.1 
27 
2-NAP 27 
13C6 1-NAP 222.1 → 191.2 
27 
13C6 2-NAP 27 
9-FLU 
254.1 → 165.0 
23 
3-FLU 20 
2-FLU 20 
13C6 9-FLU 
260.1 → 170.9 
23 
13C6 3-FLU 30 
13C6 2-FLU 30 
4-PHE 234.8 → 220.0 30 
13C4 4-PHE 270.1 → 238.8 30 
3-PHE 
266.1 → 235.2 
27 
2-PHE 27 
1-PHE 27 
13C6 3-PHE 272.1 → 241.3 
27 
13C6 2-PHE 27 
13C4 1-PHE 270.1 → 239.3 27 
1-PYR 290.1 → 258.9 30 
13C6 1-PYR 296.1 → 265.2 30 
 
 
  
7. Calibration and Calibration Verification 
 
a. Tuning and Calibration of Mass Spectrometer 
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The Agilent 7000A GC-MS/MS should be tuned before each analytical run.  Under 
the Instrument menu in the MassHunter Workstation Software Data Acquisition 
window, select “MS Tune” to open the tune window.  Select the “Autotune” tab and 
then the “Autotune” tab again in the lower view. Select “EI high sensitivity autotune” 
from the options and “Print Autotune report” if desired, then click the “Autotune” 
button.  Once the autotune is complete and saved, review the results either by 
printout (if that option was selected) or by the PDF that was auto-generated by the 
software.  The abundance of m/z 69 should be >1,000,000, and the isotope ratio of 
m/z 70 to m/z 69 should be roughly 1%.  The relative abundance of m/z 502 to m/z 
69 should be >2.5%, and the isotope ratio of m/z 503 to m/z 502 should be roughly 
10%.  The repeller voltage should be <16 V.  The EMV (Gain) should be < 2000 V 
and gain factor >200. If these values are not met, proceed to clean the ion source or 
perform other maintenance as needed. 
 
b. Creation of Calibration Curve  
 
1) Calibration data 
 
A full calibration curve is analyzed with every analytical run. A linear log-log 
calibration curve, using eight ECS with concentrations ranging from 1 to 1000 
pg/µL (4 to 4,000 pg/µL for 1- and 2-NAP), is generated using the log ratio of 
the analyte peak area to the labeled internal standard peak area against the log 
ratio of the native analyte concentrations to those of the labeled internal 
standards.  The concentrations in ECS correspond to 10 - 10,000 pg/mL urine 
for all analytes except for 1- and 2-NAP, and 40-40,000 pg/mL urine for 1-NAP 
and 2-NAP.  For urine samples with concentrations higher than the calibration 
curve, the highest two standards for 1- & 2-NAP are prepared to extend the 
calibration curve and to accurately quantify those samples up to 160,000 pg/mL 
urine.  
 
2) Evaluation of Curve Statistics 
 
The R-squared value of the curve must be equal to or greater than 0.98.  
Linearity of the standard curve must extend over the entire calibration range.  
 
3) Use of the Calibration Curve 
 
The lowest point on the calibration curve is the lowest reportable level and the 
highest point is the highest reportable level.  The remainders of the points are 
distributed between these two extremes, with the majority of points in the 
concentration range where most unknowns fall. When sample results are over 
the highest reportable level, the samples are repeated with up to 50 fold 
dilution.   
  
c. Calibration Verification  
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1) Calibration verification is not required by the manufacturer. However, it should be 
performed after any substantive changes in the method or instrumentation (e.g., 
new internal standard, change in instrumentation), which may lead to changes in 
instrument response, have occurred. 
 
2) All calibration verification runs and results shall be appropriately documented. 
 
3) According to the updated Clinical Laboratory Improvement Amendments (CLIA) 
regulations from 2003 the requirement for calibration verification is met if the test 
system’s calibration procedure includes three or more levels of calibration 
material, and includes a low, mid, and high value, and is performed at least once 
every six months. 
 
4) All of the conditions above are met with the calibration procedures for this 
method. Therefore, no additional calibration verification is required by CLIA. 
 
 
8. Procedure Operation Instructions; Calculations; Interpretation of Results 
 
An analytical run consists of eight calibration standards, two blanks, two QCLs, two 
QCHs and 34 unknown urine samples. 
 
a. Sample Preparation 
 
1) Enzyme Hydrolysis 
 
Allow urine samples and QCs to thaw and reach room temperature.  Aliquot 1 
mL of urine (or 1 mL of D.I. H2O as blank) into a 16x100 mm test tube.  Add 1 
mL of 1 M sodium acetate butter (pH = 5.5) containing β-glucuronidase/ 
arylsulfatase enzyme from Helix pomatia (10 mg enzyme/1 mL buffer) into the 
test tube. Place the uncapped sample tubes on the Gilson 215 liquid handler 
(Gilson Inc., Middleton, WI) and initiate the automated spiking procedure.  All 
samples are spiked with 40 µL of I.Q.S on the Gilson 215 liquid handler. Cap 
the test tubes and invert gently several times to mix well.  Place the samples in 
a 37 ºC oven and incubate the sample overnight (~17-18 hours).     
 
2) Automated Liquid-Liquid Extraction 
 
Add D.I. water (3 mL) to all samples prior to using the Gilson 215 liquid handler 
(Gilson Inc., Middleton, WI) fitted with an 818 AutoMix for automation. Place the 
uncapped sample tubes in the Gilson 215 and initiate the extraction procedure. 
The automated procedure will add 20% toluene/80% pentane (5 mL) to each 
sample.  Manually cap the tubes then place back on the AutoMix to mix for 5 
minutes (20 rpm). Centrifuge samples at 2800 rpm on an AllegraTM 6 
centrifuge (Beckman Coulter Inc., Fullerton, CA) until clear separation can be 
seen between layers (20-30 minutes). Uncap the tubes and return them to the 
Gilson 215 to resume automation.  The liquid handler probe will transfer the 
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organic phase to clean 16x100 test tubes.  Repeat extraction a second time 
which gives a total of approximately 9mL of organic phase collected in each 
test tube. The urine sample test tubes are no longer needed and may be 
discarded.   
 
3) Evaporation 
 
Spike the extract with 10 µL dodecane and place in a RapidVap evaporator.  
The evaporation is a two-stage process.  First, the pentane fraction is 
evaporated at 45 ºC, with 40% rotation speed, and 400-450 mbar vacuum (~10 
minutes).  Then, the sample tube is transferred to a second RapidVap, and the 
toluene fraction is evaporated to a final volume of ~10uL at 80 ºC, with 50% 
rotation speed, and 200-230 mbar vacuum (20-25 minutes).  Spike each 
sample tube with 20 µL R.S.S., vortex for a few seconds, and then transfer the 
contents to an amber autosampler vial. 
 
4) Derivatization 
 
Add 10 µL of MSTFA into the GC vial and then displace the air in the vial with a 
gentle stream of argon.  Quickly screw a cap onto the vial.  Place the vials in an 
incubator or oven set at 60 ºC for 30 minutes.  The samples are then ready for 
analysis on the mass spectrometer.   
 
b. Instrument and software setup for the GC-MS/MS 
 
1) Preliminary MS/MS System Setup and Performance Check  
 
The MS/MS tune must be verified in the MassHunter Workstation Software 
Data Acquisition window either by a new Autotune procedure (described above 
in 7a) or by performing a Check Tune. Under the Instrument menu, select “MS 
Tune” to open the tune window.  Select the “Autotune” tab and then the “Check 
Tune” tab in the lower view. Select “Print Check Tune report” if desired, then 
click the “Check Tune” button. The results of the check tune must all pass as 
“OK” and the abundance of PFTBA (69.0) should be >1000000. If these results 
are not met, the instrument is not ready for operation and maintenance 
(cleaning, check for air leaks, etc) needs to be performed. 
 
2) Final Setup and Operation  
 
a) Create the run sequence 
 
The sequence may be created in two ways: in the MassHunter software or 
in Microsoft Excel.  The choice is left to the discretion of the analyst. 
 
In the MassHunter Workstation Software Data Acquisition window, select 
“Edit sequence” under the Sequence menu. Make sure that the appropriate 
number of samples filenames, sample IDs, and sample positions are 
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included in the run sequence. Include two solvent blanks after upper level 
calibration standards.  Make sure that each sequence row is labeled for 
“Type” (Cal, Sample, etc.) and that all “Cal” standards have corresponding 
“Level.”  Ensure that the correct instrument method 
(NHANES_UU_20130611.M) is selected.  The latter defines GC, MS, and 
autosampler methods.   
 
If creating a sequence in a Microsoft Excel spreadsheet, make sure there 
are the appropriate number of rows with correct filenames, sample IDs, vial 
positions, sample types, and calibration levels (if applicable). The 
information can then be copied and pasted from Excel into the appropriate 
columns within the MassHunter sequence table.   
 
Filenames conform to the following format: AGMYYNNNN or ARMYYNNNN 
where AG = samples run on the MS/MS instrument named as AGIL, AR = 
samples run on the MS/MS instrument named as ARCHIE; M = month (A = 
January, B = February, C = March, etc.); YY = year (13 = year 2013), and 
NNNN = run number for the month.  For example, the filename AGB130012 
corresponds to the 12th sample run in February 2013 on MS/MS instrument 
AGIL. 
 
b) Start the sequence 
 
In the MassHunter Workstation Software Data Acquisition window, select 
“Run sequence” under the Sequence menu. In the pop-up window that 
appears, select “Disable Barcode for this sequence” and fill out the fields for 
Operator Name and Data File Directory.  Click RunSequence. 
 
c. Processing of Data 
 
Data is processed using the MassHunter QQQ Quantitative Analysis software. In the 
software, select raw data files and batch them by analytical run (e.g. ABC-011). 
Select and apply the quantitation method with the most recent calibration information 
(2013-06_OH-ME_ECS71-78.quantmethod.XML) to the batch. The batch is then 
analyzed and automatically integrated. Visually review, and manually correct as 
needed, the integration of each peak.  Save the batch and re-analyze to account for 
updates to the calibration curve and calculated concentrations in samples due to 
manual integrations. Export the results table as an MS Excel file, and place a copy 
of this Excel file on the CDC shared network drive. Perform all further calculations 
such as standard curve generation, QC analysis, blank analysis, limit-of-detection 
determination, unknown sample calculations, data distribution, etc. in MS Excel and 
in SAS.  Import final results and all supporting information into a SAS dataset and 
save it on the share drive.   
 
d. Replacement and Periodic Maintenance of Key Components 
 
1) Agilent 7000A GC/MS/MS Mass Spectrometer 
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• Clean the ion source every 4-6 weeks or sooner as needed 
• Replace the ion source filaments every 4 months or sooner as needed 
• Replenish the calibration gas every 12 months or sooner as needed 
• Trained Agilent technicians perform all other maintenance based on an 
annual schedule, or as needed 
2) Agilent 7890A GC  
 
• Clean the injection port and change the injection port liner and septum 
biweekly or sooner as needed 
• Cut the GC column as needed 
• Replace the GC column after 2000 injections or sooner as needed 
• Replace Helium tank when the pressure is below 500 psi 
  
9. Reportable Range of Results 
 
The linear range of the standard calibration curves determines the highest and lowest 
analytical values of an analyte that are reportable.  The calibration verification of the 
method encompasses this reportable range.  However, urine samples with analytical 
data values exceeding the highest reportable limit may be re-extracted using a smaller 
volume (e.g., 0.2 mL or 5 fold dilution) and re-analyzed so that the result is in the 
reportable range. For samples with extremely high values, samples can be diluted up to 
50 folds (0.02 mL sample size).  
 
a. Linearity Limits 
 
Analytical standards are linear for all analytes through the range of concentrations 
evaluated.  The linear range is 40 pg/mL to 160,000 pg/mL urine for 1-NAP and 2-
NAP and 10 pg/mL to 20,000 pg/mL urine for the remaining analytes.  Urine samples 
whose OH-PAH concentrations exceed these ranges must be diluted and re-
analyzed using a smaller aliquot (first use 0.2mL, and then 0.02 mL if needed). 
 
b. Limit of Detection 
 
The limit of detection (LOD) for each analyte is defined as the higher LOD calculated 
by two methods, 1) In relation to method blanks: as three times the standard 
deviation of the method blanks run over a 6-month period of time; 2) In relation to 
instruments detection limit: defined as the lowest point on the calibration curve 
verified to give a signal with the signal-noise-ratio (S/N) equal to or greater than 10. 
The detection limits determined for each analyte are evaluated periodically (e.g. 
every 6 months or after an NHANES cycle) based on observed blank levels over the 
period. Typical LODs are presented in Table 8 (updated after NHANES 2011-12). 
 
Table 8.  Limits of detection (LOD)  
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Analyte LOD (pg/mL) 
1-NAP 48 
2-NAP 40 
9-FLU 10 
2-FLU 10 
3-FLU 10 
1-PHE 10 
2-PHE 10 
3-PHE 10 
4-PHE 10 
1-PYR 10 
 
c. Precision 
 
The precision of the method is reflected in the variance of quality control samples 
analyzed over time.  The mean and coefficients of variation (CV) of 318 QC samples 
are listed in Table 9.  These QC samples were prepared over 6 months by two 
different analysts using two automated liquid handlers and two GC/MS/MS 
instruments. 
 
Table 9.  Mean, standard deviation, and CV for QC samples. The parameters are QC 
pool specific.  
 
Analyte 
Low QC (n=30) High QC (n=30) 
Mean 
(pg/mL) 
Between 
day SD 
(pg/mL) 
Within 
day SD 
(pg/mL) 
CV  
Mean 
(pg/mL) 
Between 
day SD 
(pg/mL) 
Within 
day SD 
(pg/mL) 
CV  
1-NAP 812 55 27 6.3% 1233 111 59 8.3% 
2-NAP 1807 112 65 5.6% 2273 153 102 5.9% 
9-FLU 310 23 9 7.3% 628 48 24 7.1% 
3-FLU 268 22 9 7.9% 689 56 28 7.6% 
2-FLU 465 28 12 5.6% 789 85 31 10% 
4-PHE 317 18 9 5.2% 773 42 31 4.7% 
3-PHE 273 17 9 5.8% 704 40 31 4.8% 
1-PHE 274 17 10 5.7% 691 45 31 5.6% 
2-PHE 210 29 8 13% 596 81 25 13% 
1-PYR 348 26 17 6.5% 906 71 58 6.4% 
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d. Analytical Specificity 
 
The use of a triple-quadrupole MS allows a means of monitoring ion/mass transitions 
specific to each analyte.  The analyte peaks are located in well-defined regions of 
the chromatogram with no visible interferences and low background.  The retention 
time for the analytes relative to the isotope internal standards give additional 
confirmation of the presence of analytes in the sample. The relative retention time 
(RRT) ratio of a native analyte against its labeled internal standard cannot deviate 
more than 0.15% (OH-PAHs) from that in calibration standards.   
 
e. Accuracy 
 
The accuracy of this method was evaluated by analyzing two NIST Standard 
Reference Materials (SRMs) and compared to its certified concentrations for the 10 
OH-PAHs (Table 10).  
 
Table 10. Measured concentrations using CDC method in comparison to the 
certified concentrations in two NIST SRMs 
 
 Analyte 
  
SRM 3672 Smoker urine SRM 3673 Non-smoker urine 
This 
method 
NIST 
Certified*  accuracy 
This 
method 
NIST 
Certified*  accuracy 
1-NAP 33868 
               
34,400  98% 197277 
            
211,000  93% 
2-NAP 8768 
                
8,730  100% 1342 
               
1,345  100% 
9-FLU 357 337 106% 109 110 99% 
3-FLU 404 428 94% 35 39 90% 
2-FLU 823 870 95% 94 107 88% 
4-PHE 36 49 74% 8 10 77% 
3-PHE 97 125 78% 20 28 70% 
1-PHE 141 136 103% 50 49 102% 
2-PHE 89 84 106% 23 25 94% 
1-PYR 201 173 116% 32 30 106% 
* Certified concentrations on OH-PAHs were obtained from the SRMs’ draft Certificate of Analysis 
(COAs, internal communication with Dr. Michele Schantz, NIST). Mass fraction concentrations (μg/kg) 
were converted to urinary concentration (pg/mL) using a urine density value of 1.019 g/mL, as 
specified on the COAs. 
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The accuracy of the method was further assessed in a 6-point matrix standard 
addition experiment. We spiked a urine pool with 10, 20, 50, 100, 500 and 1000 
pg/mL of standards (four times higher spike for 1- and 2-NAP). The un-spiked and 
spiked urine pools were analyzed, each in six replicates. A linear regression analysis 
was carried out by plotting the measured concentrations against spiked 
concentrations to evaluate correlations and determine concentrations of analyte in 
the non-spiked urine sample. As shown in Table 11, the matrix-spiked samples gave 
good linearity for all compounds with correlation coefficients ranging 0.92−1.00. The 
intercept from the linear regression reflected 80−109% of the measured 
concentrations in the un-spiked urine pool and the differences were not statistically 
significant (alpha = 0.05), demonstrating a non-biased and accurate method. 
 
 
Table 11. Matrix-spiked standard addition experiment parameters 
 
Analyte Slope 
Intercept 
(pg/mL) 
r2 
unspiked 
Conc (pg/mL) 
1-NAP 1.00 868 1.00 901 
2-NAP 0.98 1208 1.00 1200 
9-FLU 1.01 247 1.00 248 
3-FLU 1.02 257 1.00 255 
2-FLU 1.02 408 1.00 406 
4-PHE 0.87 10 1.00 11 
3-PHE 0.92 124 1.00 122 
1-PHE 0.98 78 1.00 82 
2-PHE 0.97 54 1.00 56 
1-PYR 1.02 109 0.99 108 
 
 
10. Quality Assessment and Proficiency Testing 
 
a. Quality Assessment 
 
Quality assessment procedures follow standard practices (6).  Daily experimental 
checks are made on the stability of the analytical system.   Blanks and standards, as 
well as QC materials, are added to each day's run sequence.  The blank and 
standard are analyzed at the beginning of each run to check the system for possible 
contamination or in the spiking solutions and/or reagents. Two QCLs and two QCHs 
are prepared and analyzed at the beginning and the end of each run; their 
concentrations are compared with acceptance criteria to assure the proper operation 
of the analysis. Relative retention times are examined for the internal standard to 
ensure the choice of the correct chromatographic peak.  
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b. Quality Control Procedures  
 
1) Individual Sample Quality Checks 
 
Each individual sample will be subjected to a number of quality checks: a) auto 
integrations must be reviewed and integrated manually if needed; b) the 
calculated recovery for the spiked C13-labeled internal standards must be 
above 15% and lower than 150%; c) the relative retention time of each analyte 
in relation to its respective internal standard must be within ±0.15% (for OH-
PAHs) of its established value. 
 
2) Establishing QC limits 
 
Quality control limits are established by characterizing assay precision with 
repetitive analyses of the QC pools.  Different variables are included in the 
analysis (e.g. multiple analysts and instruments) to capture realistic assay 
variation over time.  The mean, standard deviation (within day and between 
days), coefficient of variation, and confidence limits are calculated from this QC 
characterization data set.  Individual quality control charts for the 
characterization runs are created, examined, and quality control limits are used 
to verify assay precision and accuracy on a daily basis.  QC characterization 
statistics for OH-PAH analytes are listed in Table 9. The characterization 
statistics are pool specific. 
 
3) Quality Control Evaluation  
 
After the completion of a run, the quality control limits are evaluated to 
determine if the run is “in control.”  The quality control rules apply to the 
average of the beginning and ending analyses of each of the QC pools.  The 
quality control results are evaluated according to Westgard rules (6).  
 
Two QC pools per run with two or more QC results per pool  
 
A) If both QC run means are within 2Sm limits and individual results are within 
2Si limits, then accept the run.  
 
B) If 1 of the 2 QC run means is outside a 2Sm limit - reject run if:  
 
      a) Extreme Outlier – Run mean is beyond the characterization mean +/- 
4Sm  
      b) 3S Rule - Run mean is outside a 3Sm limit  
      c) 2S Rule - Both run means are outside the same 2Sm limit  
      d) 10 X-bar Rule – Current and previous 9 run means are on same side of 
the characterization mean  
 
C) If one of the 4 QC individual results is outside a 2Si limit - reject run if:  
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     a) Extreme Outlier – One individual result is beyond the characterization 
mean +/- 4Si  
b) R 4S Rule – Within-run ranges for all pools in the same run exceed 4Sw 
(i.e., 95% range limit). Note: Since runs have multiple results per pool for 
2 pools, the R 4S rule is applied within runs only.  
 
Abbreviations: 
 
Si = Standard deviation of individual results (the limits are not shown on the 
chart unless run results are actually single measurements). 
Sm = Standard deviation of the run means (the limits are shown on the chart). 
Sw = Within-run standard deviation (the limits are not shown on the chart). 
 
If the QC result for an analyte is declared “out of control”, the results of that 
analyte for all patient samples analyzed during that run are invalid for reporting. 
 
 
c. Proficiency Testing (PT) 
  
1) Scope of PT 
 
The proficiency testing (PT) scheme for this method is administered by an in-
house PT coordinator.  PT samples (4 different levels) were prepared in-house 
by spiking a known amount of standard into a well characterized urine pool and 
blind-coded by an in-house PT coordinator.  
 
In addition, since 2013, we participate in the German External Quality 
Assessment Scheme (G-EQUAS) for Analyses in Biological Materials, which 
covers 1-NAP, 2-NAP and 1-PYR.  G-EQUAS is organized and managed by 
the Institute and Outpatient Clinic for Occupational, Social and Environmental 
Medicine of the University of Erlangen-Nuremberg (Erlangen, Germany). The 
program, evaluation, and certification are based on the guidelines of the 
German Federal Medical Council. 
 
2) Frequency of PT 
 
For the in-house PT scheme, five samples of unknown concentrations are 
analyzed once or twice a year using the same method described for unknown 
samples.  The PT administrator will randomly select five of the PT materials for 
analysis.  A passing score is obtained if at least four of the five samples fall 
within the prescribed limits established beforehand.   
 
For G-EQUAS, two materials of unknown concentrations are sent from G-
EQUAS twice a year. The samples are analyzed using the same method 
described for unknown samples and the results are reported to G-EQUAS for 
evaluation and certification.   
OH-PAH in Urine    
  
NHANES 2009-2010 Page 23 of 38 
  
 
 
 
3) Documentation of PT 
 
For the in-house PT scheme, PT results are reviewed by the analyst and 
laboratory supervisor, and then submitted to the in-house PT Coordinator.  The 
PT results are evaluated by the PT Coordinator; the analysis passes 
proficiency testing if at least four of the five sample results deviate < 20% from 
the known value.   
 
For G-EQUAS, PT results are reviewed by the analyst and laboratory 
supervisor. The results and QC report are approved by a DLS statistician, 
Branch Chief, and DLS Director. The final results are submitted on G-EQUAS 
website.  
 
All proficiency results shall be appropriately documented.  If the assay fails 
proficiency testing then the sample preparation and instrumentation are 
thoroughly examined to identify and correct the source of assay error.   
 
 
11. Remedial Action if Calibration or QC Systems Fail to Meet Acceptable Criteria 
 
If the calibration or QC systems fail to meet acceptable criteria, suspend all operations 
until the source or cause of failure is identified and corrected.  If the source of failure is 
easily identifiable, for instance, failure of the mass spectrometer or a pipetting error, the 
problem is immediately corrected.  Otherwise, prepare fresh reagents and clean the 
mass spectrometer system.  Before beginning another analytical run, re-analyze several 
QC materials (in the case of QC failure) or calibration standards (in the case of 
calibration failure).  After re-establishing calibration or quality control, resume analytical 
runs.  Document the QC failures, review the cases with supervisor to determine 
source(s) of problem, and take measures to prevent re-occurrence of the same 
problem.  
 
 
12. Limitations of Method, Interfering Substances and Conditions 
 
This method is an isotope dilution mass spectrometry method, widely regarded as the 
definitive method for the measurement of organic toxicants in human body fluids.  By 
using tandem mass spectrometry, most interferences are eliminated.  Due to the matrix 
used in this procedure, occasional unknown interfering substances have been 
encountered.  If chromatographic interference with the native analyte or internal 
standard occurs, reject that analysis.  If repeat analysis still results in an interference 
that cannot be separated chromatographically, the results for that analyte are not 
reportable. 
 
 
13. Reference Ranges (Normal Values) 
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The reference range values for the OH-PAH metabolites, established based on the 
National Health and Nutrition Examination Survey (NHANES), can be found at 
http://www.cdc.gov/exposurereport.  
 
 
14. Critical Call Results (“Panic Values”) 
 
Insufficient data exist to correlate urinary OH-PAH concentrations with serious health 
effects in humans.  Therefore, no established “critical call” values exist.  Test results in 
this laboratory are reported in support of epidemiological studies, not for clinical 
assessments.   
 
 
15. Specimen Storage and Handling During Testing 
 
Urine specimens may reach and maintain ambient temperature during analysis.  The 
urine extracts are stored in GC vials at -70 ºC after analysis.  Current studies indicate 
(CDC data) that the extracts are stable for at least three weeks. 
 
 
16. Alternate Methods for Performing Test or Storing Specimens if Test System  Fails   
 
Alternate validated methods have not been evaluated for measuring these PAH 
metabolites in urine.  If the analytical system fails, urine extracts can be refrigerated 
until the analytical system is restored to functionality.  If long-term interruption (greater 
than 4 weeks) is anticipated, then store urine specimens at -70 oC. 
 
 
17. Test Result Reporting System; Protocol for Reporting Critical Calls (if Applicable)  
 
Study subject data is reported in both concentration units (ng/L, pg/mL, parts per trillion, 
or ppt) and adjusted based on creatinine excretion (ng/g creatinine). 
 
a. The data from each analytical run are initially processed and reviewed by the 
laboratory supervisor or Quality Control officer using MS Excel with build-in 
macros to check sample Quality Control parameters, including recovery, 
relative retention time, blank levels, calibration curve, etc.  The supervisor 
provides feedback to the analyst and/or his/her designee and requests 
confirmation of the data as needed. 
b. The Quality Control officer reviews each analytical run and identifies the quality 
control samples within each analytical run and determines whether the 
analytical run is performed under acceptable control conditions.   
c. One of the Division statisticians reviews and approves the quality control charts 
pertinent to the results being reported.  
d. If the quality control data are acceptable, the laboratory supervisor or his/her 
designee generates a memorandum to the Branch Chief, and a letter reporting 
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the analytical results to the person(s) who requested the analyses to be signed 
by the Division Director. 
e. The data are sent (generally electronically by e-mail) to the person(s) that 
made the initial request.   
f. All data (chromatograms, etc.) are stored in electronic format. 
 
Final hard copies of correspondence are maintained in the office of the Branch Chief 
and/or his/her designee and with the quality control officer. 
  
 
18. Transfer or Referral of Specimens; Procedures for Specimen Accountability and 
Tracking 
 
If greater than 1 mL of sample remains following successful completion of analysis, this 
material must be returned to storage at -70 °C in case reanalysis is required. These 
samples shall be retained until valid results have been obtained and reported and 
sufficient time has passed for review of the results. 
 
Standard record keeping (e.g., database, notebooks, and data files) is used to track 
specimens.  Specimens will only be transferred or referred to other DLS Branch 
laboratories or, if required, to CLIA certified laboratories.  Transfer is carried out through 
the DLS Samples Logistic Group.  Specimens may be stored at CDC specimen 
handling and storage facility (CASPIR). 
 
19.  Summary Statistics and QC Graphs 
See following pages 
 
 
  
2009-2010 Summary Statistics and QC Chart for 1-naphthol 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207a_URCP1H3 4 16JAN14 22JAN14 1181.38 44.79 3.8 
QC6_201207b_URCP1H4 77 16JAN14 05AUG14 1139.10 52.95 4.6 
QC5_201207a_URCP1L1 4 16JAN14 22JAN14 766.25 25.38 3.3 
QC5_201207b_URCP1L3 77 16JAN14 05AUG14 755.16 36.90 4.9 
QCL14F_URCP1L2 5 01AUG14 27AUG14 1112.20 31.33 2.8 
QCM14F_URCP1M1 5 01AUG14 27AUG14 3496.60 159.83 4.6 
 
 
 
2009-2010 Summary Statistics and QC Chart for 2-naphthol 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207a_URCP2H3 4 16JAN14 22JAN14 2178.63 136.27 6.3 
QC6_201207b_URCP2H4 80 16JAN14 31JUL14 2028.63 88.38 4.4 
QC5_201207a_URCP2L1 4 16JAN14 22JAN14 1704.50 97.11 5.7 
QC5_201207b_URCP2L3 80 16JAN14 31JUL14 1607.63 70.57 4.4 
QCL14F_URCP2L2 4 01AUG14 27AUG14 1350.13 56.62 4.2 
QCM14F_URCP2M1 4 01AUG14 27AUG14 3866.00 214.16 5.5 
 
 
 
2009-2010 Summary Statistics and QC Chart for 3-fluorene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207a_URC03H3 4 16JAN14 22JAN14 628.88 28.32 4.5 
QC6_201207b_URC03H4 80 16JAN14 31JUL14 586.10 41.78 7.1 
QC5_201207a_URC03L1 4 16JAN14 22JAN14 243.25 15.25 6.3 
QC5_201207b_URC03L3 80 16JAN14 31JUL14 229.97 17.31 7.5 
QCL14F_URC03L2 4 01AUG14 27AUG14 254.63 20.93 8.2 
QCM14F_URC03M1 4 01AUG14 27AUG14 736.25 62.72 8.5 
 
 
 
2009-2010 Summary Statistics and QC Chart for 2-fluorene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207a_URCP4H3 4 16JAN14 22JAN14 615.38 15.35 2.5 
QC6_201207b_URCP4H4 80 16JAN14 31JUL14 565.26 27.33 4.8 
QC5_201207a_URCP4L1 4 16JAN14 22JAN14 301.13 10.74 3.6 
QC5_201207b_URCP4L3 80 16JAN14 31JUL14 283.73 13.37 4.7 
QCL14F_URCP4L2 4 01AUG14 27AUG14 254.25 12.25 4.8 
QCM14F_URCP4M1 4 01AUG14 27AUG14 679.00 42.43 6.2 
 
 
 
2009-2010 Summary Statistics and QC Chart for 3-phenanthrene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207a_URC05H3 4 16JAN14 22JAN14 555.75 3.71 0.7 
QC6_201207b_URC05H4 79 16JAN14 31JUL14 516.72 20.84 4.0 
QC5_201207a_URC05L1 4 16JAN14 22JAN14 209.50 4.67 2.2 
QC5_201207b_URC05L3 79 16JAN14 31JUL14 201.82 10.54 5.2 
QCL14F_URC05L2 4 01AUG14 27AUG14 171.13 8.89 5.2 
QCM14F_URC05M1 4 01AUG14 27AUG14 506.38 29.24 5.8 
 
 
 
2009-2010 Summary Statistics and QC Chart for 1-phenanthrene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207a_URC06H3 4 16JAN14 22JAN14 728.00 9.93 1.4 
QC6_201207b_URC06H4 79 16JAN14 31JUL14 687.87 23.01 3.3 
QC5_201207a_URC06L1 4 16JAN14 22JAN14 291.38 3.38 1.2 
QC5_201207b_URC06L3 79 16JAN14 31JUL14 279.09 10.57 3.8 
QCL14F_URC06L2 4 01AUG14 27AUG14 216.50 13.15 6.1 
QCM14F_URC06M1 4 01AUG14 27AUG14 638.88 41.98 6.6 
 
 
 
2009-2010 Summary Statistics and QC Chart for 2-phenanthrene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207a_URC07H3 4 16JAN14 22JAN14 718.25 7.88 1.1 
QC6_201207b_URC07H4 76 16JAN14 31JUL14 669.76 22.02 3.3 
QC5_201207a_URC07L1 4 16JAN14 22JAN14 277.88 5.98 2.2 
QC5_201207b_URC07L3 76 16JAN14 31JUL14 264.05 10.85 4.1 
QCL14F_URC07L2 7 01AUG14 27AUG14 212.50 9.05 4.3 
QCM14F_URC07M1 7 01AUG14 27AUG14 621.14 24.12 3.9 
 
 
 
2009-2010 Summary Statistics and QC Chart for 1-pyrene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207b_URC10H4 80 16JAN14 31JUL14 737.85 42.66 5.8 
QC5_201207b_URC10L3 80 16JAN14 31JUL14 269.15 16.79 6.2 
QC6_201207a_URC10H3 4 17JAN14 05FEB14 745.25 34.30 4.6 
QC5_201207a_URC10L1 4 17JAN14 05FEB14 266.63 16.36 6.1 
QCL14F_URC10L2 4 01AUG14 27AUG14 450.63 37.60 8.3 
QCM14F_URC10M1 4 01AUG14 27AUG14 739.13 86.28 11.7 
 
 
 
2009-2010 Summary Statistics and QC Chart for 9-fluorene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207a_URC17H3 4 16JAN14 22JAN14 672.75 43.08 6.4 
QC6_201207b_URC17H4 80 16JAN14 31JUL14 646.03 33.69 5.2 
QC5_201207a_URC17L1 4 16JAN14 22JAN14 405.63 20.29 5.0 
QC5_201207b_URC17L3 80 16JAN14 31JUL14 387.01 16.89 4.4 
QCL14F_URC17L2 5 01AUG14 27AUG14 207.10 8.50 4.1 
QCM14F_URC17M1 5 01AUG14 27AUG14 560.60 46.65 8.3 
 
 
 
2009-2010 Summary Statistics and QC Chart for 4-phenanthrene 
 
 
Lot N 
Start 
Date 
End 
Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC6_201207a_URC19H2 4 16JAN14 22JAN14 546.63 7.91 1.4 
QC5_201207a_URC19L1 4 16JAN14 22JAN14 188.50 3.11 1.6 
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Appendix A ─ Ruggedness Testing for Analytical Method 
 
Procedure 
 
Ruggedness testing was conducted to evaluate 5 parameters in this method: enzyme 
amount, buffer strength, buffer pH value, de-conjugation time and de-conjugation 
temperature. For each parameter, 3 or 5 levels were tested, including 1 or 2 lower level(s), 1 
or 2 higher level(s), and the method level. An anonymous urine pool was used in the 
ruggedness experiments. Samples were run in triplicates to ensure the precision of analytical 
results. Reported below are results on the major detectable OH-PAH analytes. 
 
Results in Tables 
 
Enzyme amount 
(mg/sample) 
1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR 
Average concentration (pg/mL) 
Lower level1 5mg 32664 38389 5682 1767 3062 390 1902 1701 1387 1288 
Lower level2 9mg 33012 37555 5616 1763 3064 398 1864 1683 1371 1267 
Method 10mg 33089 37914 5629 1759 3088 483 1868 1697 1373 1271 
Higher level1 11mg 33915 39543 5641 1767 3062 489 1883 1703 1396 1291 
Higher level2 20mg 33499 38383 5653 1785 3058 485 1891 1688 1385 1275 
  Standard deviation 
Lower level1 5mg 20 432 120 5 18 10 24 12 5 15 
Lower level2 9mg 97 249 256 34 24 7 9 15 3 11 
Method 10mg 647 181 137 15 39 1 17 3 8 11 
Higher level1 11mg 1118 281 99 26 31 13 32 21 9 17 
Higher level2 20mg 312 312 90 13 21 3 10 10 4 27 
 
Buffer strength 
(M) 
1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR 
average concentration (pg/mL) 
Lower level1 0.5M 31599 35592 5706 1732 3087 492 1851 1735 1363 1221 
Lower level2 0.9M 31708 36069 5684 1746 3028 452 1860 1711 1369 1231 
Method 1M 31289 35629 5764 1753 3070 445 1856 1693 1368 1229 
Higher level1 1.1M 31310 35516 5646 1753 3040 373 1860 1707 1350 1246 
Higher level2 1.5M 32175 36013 5672 1751 3065 374 1843 1747 1358 1228 
  Standard deviation 
Lower level1 0.5M 514 533 77 27 43 45 27 38 10 18 
Lower level2 0.9M 1699 1429 145 20 17 31 25 65 23 23 
Method 1M 537 580 79 22 47 16 47 32 18 24 
Higher level1 1.1M 806 871 136 32 44 12 36 9 17 6 
Higher level2 1.5M 1098 349 102 18 81 19 32 41 25 16 
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Buffer pH 
1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR 
Average concentration (pg/mL)  
Lower level1 pH4.5 26966 34660 5554 1774 2943 442 1878 1699 1374 1188 
Lower level2 pH5.3 29123 35246 5757 1746 3061 401 1837 1671 1364 1290 
Method pH5.5 29221 36267 5773 1750 3101 467 1875 1699 1382 1263 
Higher level1 pH5.7 28717 35474 5682 1729 3019 442 1856 1630 1363 1205 
Higher level2 pH6.5 28169 36460 5863 1788 3112 440 1889 1632 1378 1243 
  Standard deviation 
Lower level1 pH4.5 182 1675 77 118 8 20 10 22 15 29 
Lower level2 pH5.3 920 718 42 21 26 50 37 17 11 23 
Method pH5.5 907 833 146 11 50 3 16 33 24 36 
Higher level1 pH5.7 547 510 203 41 75 9 45 30 31 12 
Higher level2 pH6.5 761 729 15 68 75 28 48 53 7 27 
 
De-conjugation 
time (hours) 
1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR 
Average concentration (pg/mL) 
Lower level1 4 hr 30121 39503 5721 1766 3111 478 1846 1690 1377 1246 
Lower level2 17 hr 28590 34326 5516 1740 2982 429 1741 1631 1257 1226 
Method 18 hr 28293 34936 5614 1721 2954 406 1756 1604 1268 1211 
Higher level1 19 hr 27462 34265 5521 1710 2947 411 1724 1591 1263 1201 
Higher level2 24 hr 28283 35314 5502 1729 2976 331 1769 1629 1288 1214 
  Standard deviation 
Lower level1 4 hr 484 809 146 7 19 3 19 19 15 13 
Lower level2 17 hr 261 330 74 19 36 6 21 21 22 36 
Method 18 hr 921 1158 26 3 11 7 18 12 10 2 
Higher level1 19 hr 1150 580 94 40 88 18 23 21 39 30 
Higher level2 24 hr 861 983 162 11 28 4 40 26 10 12 
 
De-conjugation 
temperature (ºC) 
1-NAP 2-NAP 9-FLUO 3-FLUO 2-FLUO 4-PHEN 3-PHEN 1-PHEN 2-PHEN 1-PYR 
Average concentration (pg/mL) 
Lower level  32ºC 28842 35031 5882 1681 3065 495 1752 1640 1355 1223 
Method 37ºC 31709 37941 5601 1738 2985 416 1727 1568 1273 1196 
Higher level 42ºC 28793 36394 5647 1730 2992 448 1813 1604 1341 1139 
  Standard deviation 
Lower level  32ºC 694 1131 122 48 55 14 22 10 19 27 
Method 37ºC 1771 2142 201 120 214 32 93 106 88 65 
Higher level 42ºC 654 733 202 44 71 16 45 41 29 28 
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Results in Graphs 
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Appendix B ─ Quick Method Guide 
 
This quick method guide was compiled for new lab analysts to get familiar with the method 
and for using in the lab for quick reference.  
 
1. The current OH-PAH Method (as of September 2013) 
The current method is a two-day method.  Urine samples are aliquoted & spiked 
on day one, deconjugated overnight, then extracted, evaporated, and derivatized 
on day two. 
 
2. Day One: 
a. Print runsheet(s) of day’s run(s). 
b. Pull samples out to thaw.  Also thaw 2 QCL and 2 QCH per sample set. 
c. Make sure that enough buffer/enzyme solution is prepared for the day’s samples.  
If not, prepare additional solution. 
d. Hand label culture tubes (2 sets, size 16x100) & conical tip centrifuge tubes 
(15mL) with run ID #s. (Note: QCs are stored in culture tubes.) 
e. Gently invert the urine specimen vial to ensure homogeneity. Aliquot 1mL urine 
into test tubes.  For blanks, use 1mL DI-water.   
f. To all samples, add 1mL buffer/enzyme solution (recommend using Eppendorf 
repeater pipette with 10mL tip) and 5uL ascorbic acid solution. 
g. Load samples onto TRACY Gilson 215 Liquid Handler. 
i. Transfer contents of one vial of IQS into clean amber V-vial & cap with new 
septum. Weigh capped V-vial with IQS for “before” weight. Note on 
runsheet. 
ii. Purge transfer lines.  
iii. Use TRACY to spike 40uL of IQS to all samples. 
iv. Weigh capped V-vial with IQS for “after” weight.   
v. Return any remaining IQS back to its GC vial.  Write date on vial cap. 
Return to refrigerator.  
h. Cap all samples with solid black phenolic caps.  Gently invert each sample twice to 
mix the buffer and urine.   
i. Incubate samples in 37°C oven overnight (~17-18) hours. 
j. Record buffer solution # & date, enzyme # & date, IQS #, and any other 
comments/observations on the runsheet. 
 
3. Day Two: 
a. Remove samples from incubation oven.  Note time on runsheet. 
b. Uncap tubes.  Add DI-water to all samples (3mL, or enough to bring total volume in 
test tube up to 5mL). 
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c. Gilson 215 Liquid Handler 
i. Place samples on Gilson 215 Liquid Handler automix.  Lock lid.  Power off 
the automix, and then turn back on.  Rotate automix until red “NOT READY’ 
light goes away. 
ii. Load pre-labeled conical tip tubes & cover with aluminum foil. 
iii. Fill solvent bottles with fresh 80/20 pentane/toluene. 
iv. Check hexane level.  Replace if necessary. 
v. Check waste level.  Replace if necessary. 
vi. Open Trilution LH software.  Log on as Administrator, no password is 
required. The interface will open & default to the Liquid Handling menu. 
vii. Click once on the Application bar to open the Application window. 
viii. In the left pane, click the [+] next to Applications.  Our method is OHPAH 
Full Method.  Double-click to select it. 
ix. The top pane will load all the methods that make up the application.  The 
lower pane will show the Gilson 215 bed layout.   
x. The default settings are for a batch of 20 samples, as shown in the ‘#Range 
of Samples’ & ‘Number of Samples’ columns. If running more than 20 
samples, you will need to change those entries. 
xi. Return to the desktop & open Home818.exe.  A small popup will appear.  If 
not already preset, enter Unit ID = 20 & the appropriate tilt (OMAR = 6 clicks 
to the right; SIM = 15 clicks to the right).  Click Send Calibration. 
xii. Return to Application window.  
xiii. Make sure all samples are loaded, the automix is properly locked, all 
solution bottles are sufficiently filled, and all empty glass tubes are loaded in 
the correct position. 
xiv. Click RUN button in bottom left of window.  A popup will ask to refresh the 
run name.  Click YES.  The application will run. 
xv. At first prompt, take samples out of automix & cap with solid caps.  Return 
to automix. Power off the automix, and then turn back on.  Rotate automix 
until red “NOT READY’ light goes away. Click OK on prompt. 
xvi. After 5 minute mix, another prompt will appear.  Move samples from 
automix to the centrifuge.  Centrifuge until 2 layers are clearly separated.  
Usually, this needs two (2) 15-20 minute periods in the centrifuge. 
xvii. Load samples back to automix rack UNCAPPED.  Return rack to automix. 
Power off the automix, and then turn back on.  Rotate automix until red 
“NOT READY’ light goes away.  Click OK on prompt. 
xviii. Turn on both RapidVaps to preheat.   
xix. Repeat steps xv-xvii for second solvent extraction.  Application will be 
finished after this step. 
 
d. Evaporate extracts in the RapidVaps.   
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i. Spike 10uL dodecane into each sample, using Eppendorf repeater pipette & 
0.1 mL tip. 
ii. Load samples into preheated 45*C RapidVap and evaporate under 400-
450mbar vacuum at 40% rotation speed until ~1-2 mL remains. This step 
takes ~10 minutes. 
1. Note time on runsheet. 
2. Print labels for your GC vials.  
a. On SIM’s computer, open Brady LabelMark software.  Choose 
Part Family – Standard, Printer Type – TLS2200/TLS PC Link, 
Label Part – PTL-72-461. Click OK. 
b. Under the Tools menu, choose ‘Create Template.’ Type your 
desired template info on the label.  At the end of each line of 
text, click the lock icon in the lower left corner.  When done 
creating template, click the save icon in the lower left corner.  
Give template a name or overwrite an existing template. 
Minimize the template. 
c. Under the File menu, choose ‘Open Template’ and choose the 
template you just created. 
d. Above the labels are a row of buttons.  Click the ‘SN’ button.  
Enter the first sample number (1) and your last sample 
number (most likely 40) then click ‘Generate.’ When you’ve 
created all the labels you need for that set of samples, click 
the printer icon to print.  
3. Label your GC vials. 
iii. Move extracts to 80*C RapidVap with 50% rotation speed and 200-230mbar 
vacuum and evaporate until ~10uL remains.   
1. This step will take roughly 25-30 minutes. 
2. Use this time wisely: fill out runsheet, prep next set of samples, label 
tomorrow’s glassware, start dishwasher, clean up, etc. 
e. Using Eppendorf repeater, reconstitute samples by spiking 20uL Recovery 
Standard (RS) into each tube.  Vortex tubes for roughly 5 seconds. 
f. Transfer extracts to labeled GC vials using electronic Rainin pipette. 
g. Using Eppendorf repeater, spike 10uL MSTFA into all vials.   
h. Displace air in MSTFA vial and GC vials using a gentle stream of Argon.  Cap 
vials. 
i. Derivatize extracts in 60*C oven for 30 minutes.  Use this time to fill out any 
missing information on the runsheet. 
j. When the extracts are ready, give them to the analyst.  Make sure your runsheet is 
complete before you give the samples to the analyst! 
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Appendix C ─ Matrix and non-matrix calibration curve 
comparison 
 
Four different types of calibration curves were prepared. They are solvent based (current in 
use), water-spiked, synthetic urine spiked, and urine-spiked calibration curves. The urine-
spiked curve is referred to matrix calibration curve, and the remaining three types of curves 
are non-matrix curves. An experiment was set up to compare the slopes from these four 
types of calibration curves, according to the DLS Policy and Procedure Manual (Version 
February 27, 2012), Section 10.5.  
 
Slope 
 
1-nap 2-nap 9-fluo 3-fluo 2-fluo 4-phen 3-phen 1-phen 2-phen 1-pyr 
Solvent 0.96 0.89 0.99 1.10 1.15 2.00 1.36 0.97 0.94 1.36 
Water 0.94 0.89 0.97 1.08 1.14 2.01 1.36 0.96 0.94 1.31 
Syn-urine 0.96 0.89 0.97 1.09 1.14 2.00 1.36 0.96 0.94 1.31 
Urine 0.93 0.89 0.97 1.08 1.14 1.93 1.36 0.96 0.93 1.31 
           
% difference compared to urine-spiked curve 
Solvent 3.5% 0.5% 1.4% 1.5% 1.5% 3.7% -0.3% 0.6% 0.4% 3.5% 
Water 1.4% 0.6% -0.4% -0.1% 0.4% 4.2% -0.1% -0.7% 0.2% -0.6% 
Syn-urine 3.2% 0.7% -0.1% 0.2% 0.2% 3.7% 0.3% -0.9% 0.4% -0.7% 
Urine 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
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Appendix D ─ Method Comparison Graphs 
 
Method comparison was performed by running 100 clinical samples using the previous 
method by Thermo Quantum GC/MS/MS (Method #6703.03) and the updated method 
(Method #6703.04) by Agilent GC/QQQ 7000 GC/MS/MS. The results are evaluated by both 
the linear regression plots between the Thermo (“ZEUS”) and Agilent (“AGIL”) results, as well 
as Bland-Altman plots by plotting the differences between the results from the two methods 
against the mean of the two results.  
 
Linear regression plots: New method “AGIL” vs. old method “ZEUS”  
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Bland-Altman plots: Difference (AGIL-ZEUS) vs. Mean of AGIL and ZEUS 
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Laboratory Procedure Manual 
  
 
Analyte: Monohydroxy-Polycyclic Aromatic 
Hydrocarbons (OH-PAHs) 
 
Matrix: Urine 
 
Method:  Isotope Dilution Gas 
Chromatography/High Resolution Mass 
Spectrometry (GC/HRMS)  
 
Method No: 09-OD 
 
Revised: 10/03/2006    
 
  as performed by: 
 
Organic Analytical Toxicology Branch 
Division of Laboratory Sciences 
National Center for Environmental Health 
 
contact:  
Andreas Sjodin, Ph.D. 
PAH Biomarker Laboratory  
Phone:  770-488-4711  
Fax:    770-488-0142 
Email:  ASjodin@cdc.gov 
 
 
Dr. Eric J. Sampson, Director 
Division of Laboratory Sciences 
 
    
Important Information for Users 
The Centers for Disease Control and Prevention (CDC) periodically refines these laboratory methods.  It is the 
responsibility of the user to contact the person listed on the title page of each write-up before using the analytical 
method to find out whether any changes have been made and what revisions, if any, have been incorporated.  
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This document details the Lab Protocol for NHANES 2003–2004 data. 
 
A tabular list of the released analytes follows: 
 
Data File 
Name 
Variable 
Name SAS Label 
URXPO1 1-napthol (ng/L) 
URXPO2 2-napthol 
URXPO3 3-fluorene 
URXPO4 2-fluorene 
URXPO5 3-phenanthrene 
URXPO6 1-phenanthrene 
URXPO7 2-phenanthrene 
URXP10 1-pyrene 
URXP17 9-fluorene 
l31pah_c 
URXP19 4-phenanthrene 
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1.  Clinical Relevance and Summary of Test Principle 
 
a. Clinical Relevance 
 
Polycyclic aromatic hydrocarbons (PAHs) are a class of ubiquitous environmental 
contaminants formed during incomplete combustion processes. Many of them have 
been identified as suspected human carcinogens (1).  Common routes of 
occupational exposure may include work involving diesel fuels and coal tars such as 
paving and roofing.  Possible environmental exposures include smoking, diet, smog 
and forest fires (2, 3).  Application of this method to analyze samples obtained from 
participants in the National Health and Nutrition Examination Survey (NHANES) will 
help determining the reference range of these chemicals in general U.S. population, 
aged 6 years and higher. 
 
b. Test Principle 
 
The specific analytes measured in this method are monohydroxy-PAH (OH-PAH).  
The procedure involves enzymatic hydrolysis of urine, extraction, derivatization and 
analysis using capillary gas chromatography combined with high resolution mass 
spectrometry (GC-HRMS) (4, 5).  This method uses isotope dilution with carbon-13 
labeled internal standards.  Ions from each analyte and each carbon-13 labeled 
internal standard are monitored, and the abundances of each ion are measured.  
The ratios of these ions are used as criteria for evaluating the data.  The analytes 
measured in this procedure are shown in Table 1.  By evaluating these analytes in 
urine, a measurement of the body burden from PAH exposure is obtained. 
 
Table 1. Analytes measured, their parent compounds, and their abbreviations.  
No. Parent PAH Metabolite/Analyte Abbreviation 
1 Naphthalene 1-hydroxynaphthalene 1-NAP 
2 Naphthalene 2-hydroxynaphthalene 2-NAP 
3 Fluorene 9-hydroxyfluorene 9-FLUO 
4 Fluorene 2-hydroxyfluorene 2-FLUO 
5 Fluorene 3-hydroxyfluorene 3-FLUO 
6 Phenanthrene 1-hydroxyphenanthrene 1-PHEN 
7 Phenanthrene 2-hydroxyphenanthrene 2-PHEN 
8 Phenanthrene 3-hydroxyphenanthrene 3-PHEN 
9 Phenanthrene 4-hydroxyphenanthrene 4-PHEN 
11 Fluoranthene 3-hydroxyfluoranthene 3-FLRAN 
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12 Pyrene 1-hydroxypyrene 1-PYR 
No. Parent PAH Metabolite/Analyte Abbreviation 
13 Benzo[c]phenanthrene 1-hydroxybenzo[c]phenanthrene 1-BCP 
14 Benzo[c]phenanthrene 2-hydroxybenzo[c]phenanthrene 2-BCP 
15 Benzo[c]phenanthrene 3-hydroxybenzo[c]phenanthrene 3-BCP 
16 Benz[a]anthracene 1-hydroxybenz[a]anthracene 1-BAA 
17 Benz[a]anthracene 3-hydroxybenz[a]anthracene 3-BAA 
18 Benz[a]anthracene 9-hydroxybenz[a]anthracene 9-BAA 
19 Chrysene 1-hydroxychrysene 1-CHRY 
20 Chrysene 2-hydroxychrysene 2-CHRY 
21 Chrysene 3-hydroxychrysene 3-CHRY 
22 Chrysene 4-hydroxychrysene 4-CHRY 
23 Chrysene 6-hydroxychrysene 6-CHRY 
24 Benzo[a]pyrene 3-hydroxybenzo[a]pyrene 3-BAP 
25 Benzo[a]pyrene 7-hydroxybenzo[a]pyrene 7-BAP 
 
 
2. Safety Precautions 
 
a. Reagent toxicity or carcinogenicity 
 
Some of the reagents necessary to perform this procedure are toxic.  Special care 
must be taken to avoid inhalation or dermal exposure to the reagents necessary to 
carry out the procedure. 
 
b. Radioactive hazards 
 
There are no radioactive hazards associated with this procedure. 
 
c. Microbiological hazards 
 
Although urine is generally regarded as less infectious than serum, the possibility of 
being exposed to various microbiological hazards exists.  Appropriate measures 
must be taken to avoid any direct contact with the specimen (See Section 2.e.). CDC 
recommends a Hepatitis B vaccination series and a baseline test for health care and 
laboratory workers who are exposed to human fluids and tissues.  Observe 
Universal Precautions. 
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d. Mechanical hazards 
 
There are only minimal mechanical hazards when performing this procedure using 
standard safety practices.  Laboratorians must read and follow the manufacturer’s 
information regarding safe operation of the equipment.  Avoid direct contact with the 
mechanical and electronic components of the mass spectrometer unless all power to 
the instrument is off.  Generally, mechanical and electronic maintenance and repair 
must only be performed by qualified technicians.  The autosampler and the mass 
spectrometer contain a number of areas which are hot enough to cause burns.  
Precautions must be used when working in these areas. 
 
e. Protective equipment 
 
Standard safety precautions must be followed when performing this procedure, 
including the use of a lab coat/disposable gown, safety glasses, appropriate gloves, 
and chemical fume hood.  Refer to the laboratory Chemical Hygiene Plan and CDC 
Division of Laboratory Sciences safety policies and procedures for details related to 
specific activities, reagents, or agents.        
 
f. Training 
 
Formal training in the use of a high resolution mass spectrometer is necessary.  
Users are required to read the operation manuals and must demonstrate safe 
techniques in performing the method. Anyone involved in sample preparation must 
be trained in all sample preparation equipment, chemical handling, and have basic 
chemistry laboratory skills. 
 
g. Personal hygiene 
 
Follow Universal Precautions.  Care must be taken when handling chemicals or any 
biological specimen.  Routine use of gloves and proper hand washing must be 
practiced.  Refer to the laboratory Chemical Hygiene Plan and CDC Division of 
Laboratory Sciences safety policies and procedures for details related to specific 
activities, reagents, or agents. 
 
h. Disposal of wastes 
 
Waste materials must be disposed of in compliance with laboratory, federal, state, 
and local regulations.  Solvents and reagents must always be disposed of in an 
appropriate container clearly marked for waste products and temporarily stored in a 
chemical fume hood.  All disposable items that come in direct contact with the 
biological specimens are to be placed in a biohazard autoclave bag that must be 
kept in appropriate containers until sealed and autoclaved.  The unshielded needles, 
pipette tips and disposable syringes must be placed immediately into a sharps 
container and autoclaved when this container becomes full. Wipe down all surfaces 
with a freshly prepared bleach solution (a 10% dilution of commercial sodium 
hypochlorite (bleach) or equivalent) when work is finished.  Any non-disposable 
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glassware or equipment that comes in contact with biological samples must be 
washed with bleach solution before reuse or disposal.  Any other non-disposable 
glassware must be washed and recycled or disposed in an appropriate manner. 
 
Observe Universal Precautions.  Dispose of all biological samples and diluted 
specimens in a brown glass bottle; disinfect the bio-hazardous material with bleach 
(10% in final volume), and dispose according to CDC/DLS guidelines for disposal of 
hazardous waste. Dispose all used disposable laboratory supplies (tubes, pipette tips, 
etc.) in an autoclave bag at the end of the analysis according to CDC/DLS guidelines 
for disposal of hazardous waste. 
 
 
3. Computerization; Data-System Management  
 
a. Software and knowledge requirements 
 
This method has been validated using the Thermo Finnigan GC/HRMS system 
controlled by XcaliburTM Software 1.3.  Analyte peaks are integrated by Quan 
Browser under XcaliburTM.  Results are exported from Quan Browser result files to 
Microsoft Excel files that are subsequently used for calculations. Final results are 
stored in Excel format.  Knowledge of and experience with these software packages 
(or their equivalent) is required to utilize and maintain the data management 
structure. 
 
b. Sample information 
 
Information pertaining to particular specimens is entered into the database either 
manually or electronically transferred.  The result file is transferred electronically into 
the database.  No personal identifiers are used, and all samples are referenced to a 
blind coded sample identifier. 
 
c. Data maintenance 
 
All sample and analytical data are checked prior to being entered into the MS Excel 
for transcription errors and overall validity.  The database is routinely backed up 
locally through the standard practices of the NCEH network.  The local area network 
manager must be contacted for emergency assistance. 
 
d. Information security 
  
Information security is managed at multiple levels.  The information management 
systems that contain the final reportable results are restricted through user ID and 
password security access. The computers and instrument systems that contain the 
raw and processed data files require specific knowledge of software manipulation 
techniques and physical location.  Site security is provided at multiple levels through 
restricted access to the individual laboratories, buildings, and site.  Confidentiality of 
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results is protected by referencing results to blind coded sample IDs (no names or 
personal identifiers have used). 
 
 
4. Procedures for Collecting, Storing, and Handling Specimens; Criteria for 
Specimen Rejection 
 
a. Special instructions 
 
No special instructions such as fasting or special diets are required. 
 
b. Sample collection 
 
Urine specimens are collected from subjects in standard urine collection cups.  
Samples must be refrigerated as soon as possible, and must be transferred to 
specimen vials within 24 hours of collection.  A minimum of 5 milliliters of urine is 
collected and poured into sterile vials with screw-cap tops.  The specimens are then 
labeled, frozen immediately to -20 ºC, and stored on dry ice for shipping.  Special 
care must be taken in packing to protect vials from breakage during shipment.  All 
samples in long-term storage must be kept at -70 ºC until analysis. 
 
c. Sample handling 
 
In general, urine specimens must be transported and stored at frozen (< -10 ºC). 
Once received, they can be frozen at -70 ± 10 °C until time for analysis.  Portions of 
the sample that remain after analytical aliquots are withdrawn must be refrozen at 
-70 ± 10 °C.  Samples are not compromised by repeated freeze and thaw cycles.   
 
d. Sample quantity 
 
The minimum amount of specimen required for analysis is 0.5 mL, with the optimal 
amount being 2.0 mL. 
 
e. Unacceptable specimens 
 
Specimens must be frozen at a minimum of -20 ± 5 °C when delivered to the lab. 
The minimum volume required is 0.5 mL.  If either of these criteria is violated, then 
specimen must be rejected. Specimens are also rejected if suspected of 
contamination due to improper collection procedures or devices.  Specimen 
characteristics that may compromise test results include contamination of urine by 
contact with dust, dirt, etc. from improper handling.  Samples with visible 
microbiological growth (e.g. mold, bacteria) must also be rejected.  In all cases, 
request a second urine specimen if available.  A description of reasons for each 
rejected sample must be recorded on the sample transfer sheet, such as low sample 
volume, leaking or damaged container. 
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5. Procedures for Microscopic Examinations; Criteria for Rejecting Inadequately 
Prepared Slides 
 
Not applicable for this procedure. 
 
 
6. Preparation of Reagents, Calibration Materials, Control Materials, and all Other 
Materials; Equipment and Instrumentation 
 
a. Reagents and sources 
 
See Table 2. 
 
Table 2. Reagents and the Respective Manufacturers 
Reagent Manufacturers* 
organic de-ionized water (D.I. H2O) Prepared in house, CDC (Aqua Solutions, 
Inc.) 
β -glucuronidase/arylsulfatase, H-1, powder 
enzyme 
Sigma Chemical, St. Louis, MO 
pentane, hexane, acetonitrile, toluene, and 
methanol (ABSOLV grade) 
Tedia Company, Fairfield, OH 
glacial acetic acid Sigma Chemical, St. Louis, MO 
sodium acetate  Sigma Chemical, St. Louis, MO 
N-methyl-N-(trimethylsilyl)-
trifluoroacetamide (MSTFA) 
Sigma Chemical, St. Louis, MO 
argon, nitrogen Air Products and Chemicals, Allentown, PA 
13C6 1-NAP Synthesized in house, CDC 
13C6 1-PYR, 13C6 3-FLRAN,  TerraChem, Merriam, KS 
13C6 3-PHEN, 13C6 6-CHRY, 13C6 1-BAA, 
13C6 3-BAP, 13C6 4-OH-PCB79 
Cambridge Isotope Laboratories, Andover, 
MA 
Reagent Manufacturers* 
13C6 2-FLUO, 13C6 3-BCP, 13C6 3-CHRY ChemSyn, Lenexa, KS 
13C6 3-FLUO, 13C6 9-FLUO, 13C6 2-PHEN Los Alamos National Laboratory, Los 
Alamos, NM 
1-NAP, 2-NAP, 2-FLUO, 3-FLUO, 9-
FLUO, 1-PYR 
Sigma-Aldrich Chemicals, St. Louis, MO 
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1-PHEN, 2-PHEN, 3-PHEN, 4-PHEN Promochem, Wesel, Germany 
3-FLRAN, 1-BCP, 2-BCP, 3-BCP, 1-BAA, 
3-BAA, 9-BAA, 1-CHRY, 2-CHRY, 3-
CHRY, 4-CHRY, 6-CHRY, 3-BAP, 7-BAP 
Midwest Research Institute, NCI, Kansas 
City, MO 
 
* Equivalent products from other manufacturers may be used. 
 
b. Preparation of Reagents 
 
1) 1 mol/L Sodium Acetate Buffer 
 
Place 41 g sodium acetate in a 500-mL volumetric flask and add about 300 mL 
de-ionized water (D.I. H2O).  Swirl solution to dissolve sodium acetate.  Fill flask 
to the 500 mL line with D.I. H2O.  Adjust the pH to 5.5 with glacial acetic acid. 
 
2) N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) 
 
Open the sealed vial containing MSTFA from the vendor and place the MSTFA 
solution in an amber screw-cap vial (2-mL).  Displace the air over the MSTFA 
with a gentle stream of argon. The MSTFA can be stored in the microreaction 
vessel for up to 1 month.  To add MSTFA to multiple samples, use an 
Eppendorf repeator pipette with a 100-μL pipette tip, set the pipette volume at 
10 μL, and then withdraw 100 μL of MSTFA.  Discard the first two aliquots and 
the last aliquot of MSTFA (10 μL per aliquot), aliquot 10 μL into each of the 
sample vials.   
 
c. Preparation of Calibration Materials 
 
 
 
 
 
1) Stock Solutions of Individual Analytes (100 ng/μL, 400 ng/μL for 1- and 2-NAP) 
 
Approximately 5-10 mg of neat standard is weighed into a silanized screw cap 
amber vial.  Add 3 mL of acetonitrile into the vial and record the exact weight of 
the solvent.  Allow the OH-PAH to dissolve by gentle swirling or placing in an 
ultrasonic bath.  Dilute the individual standards using toluene to 100 ng/μL (400 
ng/μL for 1- and 2-NAP) with a final volume of 3.0 mL.  All solutions are stored 
in a -70 ºC freezer with an inert argon atmosphere in the vials.    
 
2) Working Standard Solution of 24 native OH-PAH mix (W.S.A) 
 
Combine 400 μL from each of the 24 native OH-PAH standard stock solutions 
in a silanized screw cap amber vial to generate the working standard solution 
(W.S.A, 4 ng/μL for each native OH-PAH concentration, except for 1- and 2-
 All OH-PAH are light sensitive and precautions to minimize exposure to light must 
be taken, such as use of UV-filtered yellow light in lab areas where samples 
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NAP at 16 ng/μL).  Homogenize the mixture by gentle swirling and vortexing.  
Solutions of other concentrations may also be prepared, if needed. Displace air 
in the vial with argon, cap the vials, and stored them at -70 ºC until needed.   
 
3) Working Standard Solution of 13 C13-labeled OH-PAH mix (W.S.I) 
 
Combine 3.76 mL of acetonitrile and 480 μL of each of the 13 13C-labeled OH-
PAH standard stock solutions (90 ng/μL) in a silanized screw cap amber vial to 
generate the working internal standard solution (W.S.I, 4 ng/μL for each of the 
13 13C-labeled OH-PAHs).  Homogenize the mixture by gentle swirling and 
vortexing.  Displace air in the vial with argon, cap the vials, and stored them at -
70 ºC until needed. 
 
4) External Calibration Standards (E.C.S)  
 
External calibration standards (E.C.S.) are prepared as presented in Table 3 
below. Concentrations for 1- and 2-NAP in all standards are 4 times higher than 
the rest of the native compounds, because these two compounds are present 
in urine samples at high concentrations. Concentrations for 13C-labeled internal 
standards are 100 pg/μL in all calibration standards. 
 
Table 3. Preparation of external calibration standards (ECS)  
 
Analytes, excluding 1- & 2-NAP 1- and 2- NAP 
Standard 
No. Concentration (pg/μL) 
Equivalent 
concentration in 
urine(pg/mL) 
Concentration 
(pg/μL) 
Equivalent 
concentration in 
urine (pg/mL) 
0 0.5 5 2 20 
1 1 10 4 40 
2 2 20 8 80 
3 5 50 20 200 
Analytes, excluding 1- & 2-NAP 1- and 2- NAP 
Standard 
No. Concentration (pg/μL) 
Equivalent 
concentration in 
urine (pg/mL) 
Concentration 
(pg/μL) 
Equivalent 
concentration in 
urine (pg/mL) 
4 10 100 40 400 
5 50 500 200 2,000 
6 100 1,000 400 4,000 
7 500 5,000 2,000 20,000 
8 1000 10,000 4,000 40,000 
9 2000 20,000 8,000 80,000 
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10 4000 40,000 16,000 160,000 
 
5) Internal Qualification Standards (I.Q.S) 
 
Measure 5.0 mL of W.S.I into a 200-mL silanized volumetric flask. Dilute the 
solution with toluene to the 200-mL line to get the internal qualification standard 
(I.Q.S).  The concentration of each 13C-labeled OH-PAH is 100 pg/μL. Aliquot 
1.7 mL of I.Q.S. into amber 2-mL standard vials, cap and seal the vials with 
Argon. Store all I.Q.S. vials in the fridge until use.  
 
6) Mass Spectrometric Check Solution 
 
This solution is used daily to monitor the operating performance of the GC 
column and the mass spectrometer.  A solution of 20 fg/μL of a tetra-
chlorinated dioxin is used as the check solution.  For a 1 μL injection, a 
minimum signal-to-noise of 4 on the m/z 321.894 peak must be obtained.   
 
d. Preparation of Control Materials 
 
1) Quality Control (QC) materials 
 
Prepare quality control materials by spiking a known amount of native OH-PAH 
mixture (in acentonitrile) into 2000 mL of an anonymous filtered urine pool (500 
pg/mL urine).  Homogenize the QC solutions overnight for equilibration.  On the 
next day aliquot the QC solutions into 16 x 100 mm test tubes (3 mL in each 
tube) and store them at -70 ± 10 °C until use.  
  
2) Recovery Spiking Solution (R.S.S) 
 
Approximately 3 mg of neat 13C6 4-OH-PCB79 is weighed into a silanized 
screw cap amber vial.  Add 3 mL of toluene into the vial and record the exact 
weight of the solvent.  Allow the standard to dissolve by gentle swirling or 
placing in an ultrasonic bath.  Methylate the standard using dioazomethane to 
obtain its methylated derivative 13C6 4-MeH-PCB79.  Dilute the methylated 
standard solution using toluene to 200 pg/μL.  This will be used as the recovery 
spiking solution (R.S.S.).  Aliquot 1.7 mL of E.R.S. into amber 2-mL standard 
vials, cap and seal the vials with Argon. Store all E.R.S. vials at 4 ± 5 °C until 
use. 
 
3) Proficiency Test Material (PT) 
 
Prepare quality control materials by spiking a known amount of W.S.A (at a 
different level as the QC) into 100 mL of an anonymous urine pool (filtered) to 
achieve the target concentration.  Prepare the urine pools at levels within the 
linear range of the method.  After spiking the urine pool with a known amount of 
W.S.A, homogenize the PT solutions overnight for equilibration.  On the next 
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day aliquot the PT solutions into 16 x 100 mm test tubes (3 mL in each tube) 
and store them at -70 ± 10 °C until use.  
 
e. Other equipment, materials, and supplies 
 
Materials / supplies and sources used during the development, validation, and 
application of this method are listed below.  Materials / supplies procured from other 
sources must meet or exceed these specifications. 
 
• Gilson 215 liquid handler (Gilson Inc., Middleton, WI) 
• 818 Automix mixer (Gilson Inc., Middleton, WI) 
• Water bath/sonicator (Branson Ultrasonics, Danbury, CT) 
• TurboVap LV evaporator (Caliper LifeSciences, Hopkinton, MA) 
• Incubator ovens (Fisher Scientific) 
• pH meter (Thermo) 
• Microbalance (Mettler-Toledo) 
• Stirring/heating plates (Corning) 
• Miscellaneous glassware (Pyrex, Kimax, Wheaton or Corning) 
• Eppendorf Repeater Plus Pipette (Brinkmann Instruments Inc., Westbury, 
NY). 
• Rainin Electronic Pipettes (Rainin, California) 
• Pasteur pipettes and bulbs (VWR). 
• Maxi-mix Vortex mixer (Barnstead International) 
• Allegra-6 centrifuge (Beckman-Coulter) 
• Amber screw top vials with various volume (Supelco, Inc., Bellefonte, PA) 
• Clear autosampler vials, 0.5 mL (SunSri) 
 
f. Instrumentation 
 
The analyses are performed on a ThermoFinnigan MAT-95XL high resolution mass 
spectrometer (Finnigan MAT, San Jose, CA) equipped with an electron impact 
ionization and interfaced to an Agilent Technologies 6890 gas chromatograph (GC) 
system (Agilent Technologies, Palo Alto, CA) 
 
1) Gas chromatograph configuration 
 
Chromatographic separation is performed on an Agilent 6890 gas 
chromatograph fitted with a J&W DB-5 30-m fused silica capillary column. The 
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column ID is 0.25-mm and the film thickness is 0.25-micron (J&W, # 22-5022 or 
equivalent).  The temperature program lasts a total of 23 minutes. (See Table 4 
for GC configuration and Table 5 for the GC temperature program.) 
 
Table 4. GC Configuration 
 
GC Parameter Setting 
Carrier gas Helium 
Constant flow rate 1 mL/minute 
GC purge flow rate 70 mL/minute 
GC saver time 5 minutes 
GC save flow rate 15 mL/minute 
Injection mode Splitless 
Injector purge delay 2 minutes 
Injector temperature 270 ºC 
 
Table 5. GC Temperature Program 
 
Time (min.) Temperature (ºC) 
0 95 
2 95 
6 160 
Time (min.) Temperature (ºC) 
20 295  
21 320 
25 320 
 
2) High Resolution Mass spectrometer (HRMS) configuration 
 
Thermo Finnigan MAT 95XL HRMS configuration is presented in Table 6.  The 
mass spectrometer is operated under Multiple Ion Detection (MID) mode.  The 
masses used to quantify analytes are presented in Table 7. 
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Table 6. Thermo Finnigan MAT 95XL HRMS Configuration  
 
HRMS Parameter Setting 
Scan mode Multiple ion detection 
Ionization type Electron impact 
Ion polarity mode Positive  
Electron energy 45 eV 
Resolution 10,000 
Ion source 250 ºC 
Conversion dynode voltage Positive 
Electron multiplier voltage 1.45 – 2.25 kV (or 106 gain) 
 
 
Table 7. Analyte Masses  
 
Analyte Molecular Ion 
[M.+] 
Confirmation Ion 
[M.+-15] 
1-NAP, 2-NAP 216.0970 201 
2-FLUO, 3-FLUO, 9-FLUO 254.1127 239 
1-PHEN, 2-PHEN, 3-PHEN, 4-PHEN 266.1127 251 
3-FLRAN, 1-PYR 290.1127 275 
3-BAP 340.1283 325 
Analyte Molecular Ion 
[M.+] 
Confirmation Ion 
[M.+-15] 
1-BCP, 2-BCP, 3-BCP, 1-BAA, 3-BAA, 9-
BAA, 1-CHRY, 2-CHRY, 3-CHRY, 4-CHRY, 
6-CHRY 
316.1283 301 
13C6 1-NAP 222.1172 207 
13C6 2-FLUO, 13C6 3-FLUO, 13C6 9-FLUO  260.1328 245 
13C6 3-PHEN, 13C6 2-PHEN 272.1328 257 
13C6 3-FLRAN, 13C6 1-PYR 272.1328 257 
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13C6 3-CHRY, 13C6 6-CHRY, 13C6 1-BAA, 13C6 
3-BCP 296.1328 281 
 
 
7. Calibration and Calibration Verification 
 
a. Calibration of Mass Spectrometer 
 
Calibrate and tune the Finnigan MAT 95XL mass spectrometer using FC43 
(perfluorotributylamine) according to the instructions in the operator’s manual 
located next to the instrument.  After calibrated with 10,000 resolution and maximum 
sensitivity, the instrument is prepared for the analysis of OH-PAHs as described in 
Section 8. 
 
b. Creation of calibration curve  
 
1) Calculation data 
 
A linear calibration curve, using eight ECS with concentration ranging from 1 to 
1000 pg/μL, is generated using the ratio of the peak area of the analyte to the 
labeled internal standard.  The concentrations in ECS correspond to 10 - 
10,000 pg/mL (40-40,000 pg/mL) levels in 2 mL urine.  For urine samples with 
concentrations higher than the calibration curve, the highest two standards 
(2000 & 4000 pg/ μL, 8,000 and 16,000 pg/μL for 1-&2-NAP) are prepared to 
extend the calibration curve and to accurately quantify those samples.  
 
2) Evaluation of curve statistics 
 
The R-squared value of the curve must be equal to or greater than 0.990.  
Linearity of the standard curve must extend over the entire standard range.  
 
3) Use of the calibration curve 
 
The lowest point on the calibration curve is the lowest reportable level and the 
highest point is above the expected range of results.  The remainders of the 
points are distributed between these two extremes, with the majority of points in 
the concentration range where most unknowns fall. 
  
c. Calibration verification  
 
In order to verify that this calibration of this test system is accurate and stable 
throughout reportable range, three E.C.S from a different batch are analyzed every 
six months.  Calculated concentration must be within 10% deviation from expected 
concentration.  
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8. Procedure Operation Instructions; Calculations; Interpretation of Results 
 
An analytical run consists of two blanks, two QCs, and 16 unknown urine samples. 
 
a. Sample Preparation 
 
All samples were prepared in a laboratory with non-UV yellow fluorescent lights. 
 
1) Hydrolysis 
 
Allow urine samples and QCs to thaw and reach room temperature.  Aliquot 2 
mL of urine sample (or 2 mL of D.I. H2O as blank) into a 16x100 mm test tube.  
Add 10 μL of I.Q.S, 1 mL of 1 M sodium acetate butter (pH = 5.5) containing β-
Glucuronidase/ arylsulfatase enzyme from Helix pomatia (10 mg enzyme/1 mL 
buffer) into the test tube.  Turn the test tube gently several times to mix well.  
Place the caps on the tube and incubate the sample at 37 ºC overnight.     
 
2) Automated Liquid-Liquid Extraction 
 
Add D.I. water (2 mL) to the sample, and extract the sample twice with pentane 
using the Gilson 215 liquid handler (Gilson Inc., Middleton, WI) for automation. 
Place the sample in the automix tray and initiate the extraction procedure. The 
automated procedure starts with adding pentane (5 mL) to the sample and 
mixing the sample by rotating it in the automix for 5 minutes (20 rpm). Then the 
procedure is paused and the sample is centrifuged at 2800 rpm on an 
AllegraTM 6 centrifuge (Beckman Coulter Inc., Fullerton, CA) for 20 minutes. 
After returning the samples to the automix tray, resume the procedure and a 
probe transfers the organic phase to clean collection tubes. This extraction 
procedure is repeated again with additional pentane (5 mL).  
 
3) Evaporation 
 
Sample extract is spiked with 5 μL dodecane and placed in a TurboVap LV 
evaporator.  Under a stream of N2 and in a 40 ºC water bath, the sample is 
evaporated to ~5 μL within 10-15 minutes.  Spike 20 μL toluene and 5 μL R.S.S 
into the sample tube, vortex the sample, and transfer the contents to clear 
autosampler vial. 
 
4) Derivatization 
 
Add 10 μL of MSTFA into the GC vial and then displace the air in the vial with a 
gentle stream of argon.  Quickly screw a cap onto the vial.  Place the vials in an 
incubator or oven set at 60 ºC for 30 minutes.  The samples are then ready for 
analysis on the mass spectrometer.  The samples may also be stored in a 
refrigerator for up to 1 week. 
 
b. Instrument and software setup for the GC/HRMS 
OH-PAH in Urine     
NHANES 2003-2004   
  
 
 16
 
1) Preliminary MAT 95 system setup and performance check  
 
Turn on the MAT 95, inject 2 μL FC-43 into the reference inlet. In the TUNE 
window, adjust resolution between 9900 and 10100.  Perform a GC/HRMS 
analysis of the mass spectrometer check solution (2, 3, 7, 8-TCDD, 10 fg/μL, 
1 μL injection) and verify chromatographic resolution and peak intensity.  In the 
lab note book, record the signal to noise of the check compound. 
 
2) Final setup and operation  
 
a) Create the run sequence 
 
In the Xcalibur Sequence Setup window, create a sequence for the run 
using the template.  Make sure that the appropriate number of samples is 
loaded, the appropriate filenames are assigned, and the appropriate sample 
positions on the autosampler tray are included in the run sequence.  Make 
sure that the correct process method and instrument method are selected.  
The latter defines GC, MID, Autosampler, and ICL methods.  The methods 
used are listed in Table 8. 
 
Table 8. GC/HRMS Methods 
 
Program Method 
Instrument  NHANES0304.met 
GC  pah_deriv.mcr 
MID  pah_deriv.mid 
Autosampler pah_1ul.mcs 
Program Method 
ICL  Sleep90.icl 5 
Process NHANES0304.pmd 
 
Filenames conform to the following format: PMYYNNN or KMYYNNN where 
P = PAH samples run on the MAT 95 instrument named as CASSI, K = 
PAH samples run on the MAT 95 instrument named as MIKE; M = month (A 
= January, B = February, C = March, etc.); YY = year (04 = year 2004), and 
NNN = run number for the month.  For example, the filename PB01012 
corresponds to PAH-February-2001-sample #12 run on MAT 95 – CASSI, 
and KD02267 would correspond to PAH-April-2002-sample #267 run on 
MAT 95 – MIKE. 
 
b) Start the sequence 
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Click Run Sequence in the main menu under Action.  Verify the sequence 
set up and make sure the whole sequence instead of one single sample is 
selected to be run.  Click OK; the system will immediately start by turning 
green on the first sample to run. 
 
3) System standby 
 
To place the MAT 95 in standby mode, enter the command .bye at the ICL 
prompt.  This command turns off the accelerator, multiplier and dynode voltage, 
and vents the reference compound (FC-43).  To reactivate the MAT 95, enter 
.run 0.50 at the command prompt.  Add the reference compound and tune. 
 
c. Processing of data 
 
After the run sequence finishes, process all raw data files in the whole sequence 
using the “NHANES0304.pmd” process method after which the analyte peaks in 
data files are automatically integrated using the process method.  Visually review 
and manually correct if needed the integration of each peak in the QuanBrowser 
window of the Xcalibur software.  Save the reviewed result file, export it as a MS 
Excel file, and save the Excel file on the Q:\ share drive.  Perform all further 
calculations such as standard curve generation, QC analysis, blank analysis, limit-of-
detection determination, unknown sample calculations, data distribution, etc. in MS 
Excel and in SAS.  Import final results and all supporting information into an RBase 
database located on the Q:\ share drive.   
 
3-BAA and 9-BAA co-elute in the GC chromatograms, so they are reported together 
as 3_9-BAA.  3-FLRAN had an interfering peak in the GC chromatograms; therefore, 
3-FLRAN is not reported. 
 
d. Replacement and Periodic Maintenance of Key Components 
 
1) MAT 95 XL Mass Spectrometer 
 
• Check cooling water level and temperature monthly 
• Clean the ion volume or replace it monthly 
• Clean the ion source or replace it annually 
• Replace the calibration gas septum monthly 
• Trained Thermo Finnigan technicians perform all other maintenance based 
on an annual schedule, or as needed 
 
2) Agilent 6890 GC 
 
• Change the injection port liner and septum daily 
• Clean the injection port, clean or replace the gold seal monthly 
• Cut the GC column for ~10” monthly or as needed 
• Replace the GC column at 1000 analyses or sooner 
• Replace Helium tank when the pressure is below 500 psi. 
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Note: Accelerate the above maintenance schedules if necessary. 
 
 
9. Reportable Range of Results 
 
The linear range of the standard calibration curves determines the highest and lowest 
analytical values of an analyte that are reportable.  The calibration verification of the 
method encompasses this reportable range.  However, urine samples with analytical 
data values exceeding the highest reportable limit may be re-extracted using a smaller 
volume and re-analyzed so that the result is in the reportable range. 
 
a. Linearity Limits 
 
Analytical standards were linear for all analytes through the range of concentrations 
evaluated.  The linear range for all analytes except 1-NAPH and 2-NAPH is 5 pg/mL 
to 40,000 pg/mL.  Calibration curves for 1-NAPH and 2-NAPH are extended to 
160,000 ng/L, because their high concentrations detected from unknown samples.   
Therefore, the linear range for 1-NAPH and 2-NAPH were 20 pg/mL to 160,000 
pg/mL.  Urine samples whose concentrations exceed these ranges must be diluted 
and re-analyzed using a smaller aliquot. 
 
b. Limit of Detection 
 
The limit of detection (LOD) for this method is defined as the higher LOD calculated 
by two methods: (i) in direct relation to method blanks prepared in parallel with the 
unknown samples, as 3 times the standard deviation of the method blanks, and (ii) 
according to the instrumental detection limit defined as the lowest point in the 
calibration curve (0.5 pg/uL, or 5 pg/mL in 2-mL urine samples) verified to give a 
signal with the S/N equal to or greater than 3. The detection limits determined for the 
analytes are presented in Table 9. 
 
Table 9.  Limits of Detection (LODs)  
 
Analyte LOD (pg/mL) 
1-NAP 18 
2-NAP 12 
9-FLUO 3.9 
2-FLUO 4.5 
3-FLUO 6.9 
1-PHEN 2.6 
2-PHEN 3.8 
3-PHEN 2.6 
4-PHEN 3.7 
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1-PYR 4.9 
1-BCP 2.8 
1-BAA 2.6 
3_9-BAA 5.2 
1-CHRY 2.6 
2-CHRY 2.6 
3-CHRY 2.6 
4-CHRY 2.6 
6-CHRY 2.6 
3-BAP 2.6 
7-BAP 2.6 
 
c. Precision 
 
The precision of the method is reflected in the variance of quality control samples 
analyzed over time.  The coefficients of variation (CV) of the method over analyses 
of six batches of QC samples (N=42) are listed in Table 10 below.  These QC 
samples were prepared over 3 weeks by four different analysts using two automated 
liquid handlers and two GC/HRMS instruments. 
 
 
 
 
Table 10.  Mean Concentration and CV for 42 QC samples  
 
Analyte Mean (pptr) CV (%) 
1-NAP 1584 2.9 
2-NAP 2912 3.3 
9-FLUO 596 2.9 
2-FLUO 559 3.0 
3-FLUO 485 2.8 
1-PHEN 391 4.4 
2-PHEN 606 3.5 
3-PHEN 533 3.2 
4-PHEN 531 3.9 
1-PYR 542 3.4 
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1-BCP 925 8.0 
2-BCP 559 3.3 
3-BCP 522 3.0 
1-BAA 528 2.7 
3_9-BAA 843 10 
1-CHRY 496 11 
2-CHRY 565 4.4 
3-CHRY 510 3.3 
4-CHRY 468 6.7 
6-CHRY 509 4.5 
3-BAP 686 6.6 
7-BAP 772 8.5 
 
d. Analytical specificity 
 
The HRMS system provides excellent analytical specificity.  The analyte peaks are 
located in well defined regions of the chromatogram with no visible interferences and 
low background.  The observation of confirmation ions (M-15 ions) confirms the 
presence of analytes of interest.  In addition, the retention time for the analytes 
relative to the isotope internal standards give additional confirmation of the presence 
of analytes in the sample.  
 
e. Accuracy 
 
Presently no established standard reference material (SRM) exists for OH-PAHs in 
human urine. Therefore, we cannot evaluate the accuracy of this method by 
analyzing an SRM and compare to its certified concentrations. Nonetheless, the 
usage of isotopically labeled internal standards can adjust for any deviates occurred 
on the OH-PAH analytes during sample preparation and instrumental analysis, and 
thus provide assurance on the accuracy of this method.   
 
 
10. Quality Assessment and Proficiency Testing 
 
a. Quality Assessment 
 
Quality assessment procedures follow standard practices6.  Daily experimental 
checks are made on the stability of the analytical system.   Blanks and standards, as 
well as QC materials, are added to each day's run sequence.  The blank and 
standard are analyzed at the beginning of each run to check the system for possible 
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contamination or in the spiking solutions and/or reagents. Two QCs are prepared 
and analyzed with each run; their concentrations are compared with acceptance 
criteria to assure the proper operation of the analysis. Relative retention times are 
examined for the internal standard to ensure the choice of the correct 
chromatographic peak.  
 
b. Quality Control Procedures  
 
1) Establishing QC limits 
 
Quality control limits are established by characterizing assay precision with 
repetitive analyses of the QC pool.  Different variables are included in the 
analysis (e.g. different analysts and instruments) to capture realistic assay 
variation over time.  The mean, standard deviation, coefficient of variation, and 
confidence limits are calculated from this QC characterization data set.   
Individual quality control charts for the characterization runs are created, 
examined, and quality control limits are used to verify assay precision and 
accuracy on a daily basis.  Typical QC characterization statistics for OH-PAH 
analytes are listed in Table 11. 
 
 
Table 11.  QC Characterization Statistics 
  
Analyte 
Mean - 3σ 
(pptr) 
Mean - 2σ 
(pptr) 
Mean 
(pptr) 
Mean + 2σ 
(pptr) 
Mean + 3σ 
(pptr) 
1-NAP 2950 3146 3536 3927 4123 
2-NAP 2201 2359 2677 2995 3153 
2-FLUOR 563 583 624 664 684 
3-FLUOR 444 460 493 527 543 
9-FLUOR 575 599 647 695 719 
1-PHEN 336 357 398 439 459 
2-PHEN 489 507 542 577 595 
3-PHEN 492 515 560 606 628 
4-PHEN 433 468 537 606 641 
1-PYR 489 507 544 581 599 
2-BCP 420 458 534 611 649 
3-BCP 460 476 508 540 557 
1-BAA 451 473 517 561 583 
3-9-BAA 446 592 885 1178 1324 
2-CHRY 359 399 479 559 599 
3-CHRY 457 477 517 557 577 
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4-CHRY 399 435 506 577 613 
6-CHRY 402 433 497 560 592 
3-BAP 228 328 528 727 827 
7-BAP 99 291 676 1060 1253 
 
2) Quality Control evaluation  
 
After the completion of a run, the quality control limits are consulted to 
determine if the run is “in control”.  The quality control rules apply to the 
average of the beginning and ending analyses of each of the QC pools.  The 
quality control results are evaluated according to Westgard rules (6): 
 
a) If both of the QCs are within the 2σ limits, then accept the run. 
 
b) If one of two QC results is outside the 2σ limits, then apply the rules below 
and reject the run if any condition is met. 
 
i. Extreme outliner: the result is outside the characterization mean by more 
than 4σ limit.  
ii. 13σ – Average of both QCs is outside of a 3σ limit. 
iii. 2 σ –QC results from two consecutive runs are2  outside of 2σ limit on the 
same side of the mean. 
iv. R4σ sequential –QC results from two consecutive runs are outside of 2σ 
limit on opposite sides of the mean. 
v. 10x sequential – QC results from ten consecutive runs are on the same 
side of the mean. 
 
If the QC result for an analyte is declared “out of control”, the results of that 
analyte for all patient samples analyzed during that run are invalid for reporting. 
 
c. Proficiency Testing (PT) 
  
1) Scope of PT 
 
There are no established PT materials; currently we are the only laboratory 
running this essay.  Therefore, the proficiency testing (PT) scheme for this 
method is administered by an in-house PT coordinator.  Because no standard 
reference materials exist for urinary analysis of hydroxy-PAH levels, PT 
samples are prepared in-house by spiking a known amount of standard into a 
well characterized urine pool, and blink-coded by in-house PT coordinator.  
 
2) Frequency of PT 
 
Four samples of unknown PT concentrations are analyzed twice a year using 
the same method described for unknown samples.  Proficiency testing must be 
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performed a minimum of once every 6 months.  The PT administrator will 
randomly select five of the PT materials for analysis.  A passing score is 
obtained if at least four of the five samples fall within the prescribed limits 
established beforehand.   
 
3) Documentation of PT 
 
Analytical PT results are reviewed by the analyst and laboratory supervisor, 
and then submitted to the in-house PT Coordinator.  The PT results are 
evaluated by the PT Coordinator; the analysis passes proficiency testing if at 
least four of the five sample results deviate < 20% from the known value.  All 
proficiency results shall be appropriately documented.  If the assay fails 
proficiency testing then the sample preparation and instrumentation are 
thoroughly examined to identify and correct the source of assay error.   
 
 
11. Remedial Action if Calibration or QC Systems Fail to Meet Acceptable Criteria 
 
If the calibration or QC systems fail to meet acceptable criteria, suspend all operations 
until the source or cause of failure is identified and corrected.  If the source of failure is 
easily identifiable, for instance, failure of the mass spectrometer or a pipeting error, the 
problem is immediately corrected.  Otherwise, prepare fresh reagents and clean the 
mass spectrometer system.  Before beginning another analytical run, re-analyze several 
QC materials (in the case of QC failure) or calibration standards (in the case of 
calibration failure).  After re-establishing calibration or quality control, resume analytical 
runs.  Document the QC failures, review the cases with supervisor to determine 
source(s) of problem, and take measures to prevent re-occurrence of the same 
problem.  
 
 
12. Limitations of Method, Interfering Substances and Conditions 
 
This method is an isotope dilution mass spectrometry method, widely regarded as the 
definitive method for the measurement of organic toxicants in human body fluids.  By 
using high resolution mass spectrometry, most interference is eliminated.  Due to the 
matrix used in this procedure, occasional unknown interfering substances have been 
encountered.  If chromatographic interference with the internal standards occurs, reject 
that analysis.  If repeat analysis still results in an interference with the internal standard, 
the results for that analyte are not reportable. 
 
 
13. Reference Ranges (Normal Values) 
 
Population-based reference ranges for 23 OH-PAH analytes were determined from a 
subset of National Health and Nutritional Survey (NHANES) 2001-2002 urine samples.  
The reference values are presented in Table 12. 
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Table 12.  Reference values from NHANES 2001-2002 (95% confidence interval in 
parentheses) 
 
Urine Concentration (ng/L) Creatinine Adjusted 
Concentration (ng/g crea.) Analyte N 
Median 95th Median 95th 
1-NAP 2748 2050      (1790-2340) 
22300 
(18000-26600)
1910      
(1700-2160) 
17800 
(14500-20800) 
2-NAP 2748 2470 (2110-2890) 
26000 
(22500-29700)
2310 
(1980-2300) 
16700 
(14100-19200) 
2-FLUO 2745 318 (277-366) 
2820 
(2340-3450) 
298 
(361-340) 
1890 
(1590-2290) 
3-FLUO 2745 134 (115-155) 
1620 
(1390-1900) 
125 
(108-144) 
1060 
(909-1290) 
9-FLUO 2745 219 (191-251) 
1090 
(950-1300) 
205 
(183-229) 
852 
(736-1120) 
Urine Concentration (ng/L) Creatinine Adjusted 
Concentration (ng/g crea.) Analyte N 
Median 95th Median 95th 
1-PHEN 2741 140 (125-158) 
684 
(581-763) 
132 
(118-147) 
464 
(404-539) 
2-PHEN 2742 54.0 (46.0-63.5) 
332 
(299-377) 
50.6 
(43.3-59.2) 
231 
(206-275) 
3-PHEN 2741 105 (92.5-118) 
649 
(542-747) 
98.0 
(87.4-110) 
428 
(360-621) 
4-PHEN 2741 41.9 (31.3-56.0) 
280 
(250-339) 
39.2 
(29.6-52.0) 
347 
(293-411) 
1-PYR 2747 49.6 (43.4-56.7) 
349 
(290-400) 
46.4 
(40.9-52.8) 
243 
(206-269) 
1-BCP 2732 <LOD 34.0 (16.0-54.0) <LOD 
41.3 
(21.0-70.8) 
2-BCP 2748 <LOD 13.0 (6.00-20.0) <LOD 
20.3 
(15.9-23.3) 
3-BCP 2748 <LOD 11.0 (8.00-16.0) <LOD 
15.9 
(14.9-16.7) 
1-BAA 2748 <LOD 30.0 (22.0-36.0) <LOD 
27.0 
(19.6-32.4) 
3_9-BAA 2748 <LOD 24.0 (19.0-31.0) <LOD 
31.8 
(28.4-35.5) 
1-CHRY 2748 <LOD 105 (85.0-138) <LOD 
89.2 
(71.4-104) 
2-CHRY 2748 <LOD 31.0 (14.0-45.0) <LOD 
27.8 
(20.9-35.0) 
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3-CHRY 2748 <LOD 42.0 (36.0-46.0) <LOD 
56.8 
(47.4-62.5) 
4-CHRY 2748 <LOD <LOD <LOD <LOD 
6-CHRY 2736 <LOD 77.0 (57.0-101) <LOD 
61.5 
(47.7-76.4) 
3-BAP 2748 <LOD 179 (139-251) <LOD 
184 
(147-248) 
 
 
14. Critical Call Results (“Panic Values”) 
 
It is unlikely that any result would be a "critical call", which would only be observed in 
acute poisonings.  There are no established “critical call” values.  Application of this 
method to NHANES studies will assist in determining levels of OH-PAH normally found 
in healthy US populations.  Test results in this laboratory are reported in support of 
epidemiological studies, not clinical assessments.  Data will help determine critical 
exposures. 
 
 
15. Specimen Storage and Handling During Testing 
 
Urine specimens may reach and maintain ambient temperature during analysis.  The 
urine extracts are stored in GC vials in a -70 ºC freezer after analysis.  Current studies 
indicate (CDC data) that the extracts are stable for three weeks. 
 
 
16. Alternate Methods for Performing Test or Storing Specimens if Test System  Fails   
 
Alternate validated methods have not been evaluated for measuring OH-PAH in urine.  
If the analytical system fails, then samples must be refrigerated (at 4 ± 3 oC) until the 
analytical system is restored to functionality.  If long-term interruption (greater that 4 
weeks) is anticipated, then store urine specimens at -70 ± 10 oC. 
 
The method is designed to run on a GC/HRMS instrument, and is not generally 
transferable to other instrumentation.  If the system fails, then samples must be 
refrigerated (at 4 ± 3 oC) until the analytical system is restored to functionality.  If long-
term interruption (greater that 4 weeks) is anticipated, then store urine specimens at -70 
± 10 oC.  Sample extracts in GC vials may be refrigerated for as long as three weeks.  If 
long-term interruption is anticipated, store sample extracts at -70 ± 10 oC. 
 
 
17. Test Result Reporting System; Protocol for Reporting Critical Calls (if Applicable)  
 
Study subject data is reported in both concentration units (ng/L) and adjusted based on 
creatinine excretion (µg/g creatinine). 
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Once the validity of the data is established by the QC/QA system outlined above, these 
results are verified by a DLS statistician, and the data reported in both hard copy and 
electronic copy.  This data, a cover letter, and a table of method specifications and 
reference range values will be routed through the appropriate channels for approval (i.e. 
supervisor, branch chief, division director) as outlined in the DLS policy and procedure 
manual.  After approval at the division level, the report will be sent to the contact person 
who requested the analyses. 
  
 
18. Transfer or Referral of Specimens; Procedures for Specimen Accountability and 
Tracking 
 
If greater than 1 mL of sample remains following successful completion of analysis, this 
material must be returned to storage at -70 ± 10 °C in case reanalysis is required. 
These samples shall be retained until valid results have been obtained and reported 
and sufficient time has passed for review of the results. 
 
Standard record keeping (e.g., database, notebooks, and data files) is used to track 
specimens.  Specimens will only be transferred or referred to other DLS Branch 
laboratories or, if required, to CLIA certified laboratories.  Transfer is carried out through 
the DLS Samples Logistic Group.  Specimens may be stored at CDC specimen 
handling and storage facility (CASPIR). 
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19. Summary Statistics and QC Graphs 
 
A. 1-naphthol  
 
Summary Statistics for 1-naphthol by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 157 12/2/2005 3/30/2006 3540.24 188.83 5.3 
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B. 2-naphthol 
 
Summary Statistics for 2-naphthol by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 156 12/2/2005 3/30/2006 2676.16 157.34 5.9 
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C. 3-fluorene  
 
Summary Statistics for 3-fluorene by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 153 12/2/2005 3/30/2006 492.08 14.53 3.0 
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D. 2-fluorene  
 
Summary Statistics for 2-fluorene by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 153 12/2/2005 3/30/2006 621.75 17.1 2.7 
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E. 3-phenanthrene  
 
Summary Statistics for 3-phenanthrene by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 148 12/2/2005 3/30/2006 560.38 18.91 3.4 
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F. 1-phenanthrene  
 
Summary Statistics for 1-phenanthrene by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 150 12/2/2005 3/30/2006 397.58 18.16 4.6 
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G. 2-phenanthrene  
 
Summary Statistics for 2-phenanthrene by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 152 12/2/2005 3/30/2006 541.17 15.22 2.8 
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 H. 1-pyrene  
 
Summary Statistics for 1-pyrene by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 152 12/2/2005 3/30/2006 544.21 17.79 3.3 
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 I. 9-fluorene  
 
Summary Statistics for 9-fluorene by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 152 12/2/2005 3/30/2006 646.52 21.14 3.3 
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J. 4-phenanthrene  
 
Summary Statistics for 4-phenanthrene by Lot 
 
Lot N Start Date End Date Mean 
Standard 
Deviation 
Coefficient of 
Variation 
QC 149 12/2/2005 3/24/2006 538.52 27.18 5.0 
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